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behorend bij het proefschrift
Angiogenesis in Mesothelioma
1. Thalidomide heeft bewezen vaatnieuwvorming te kunnen remmen bij de 
mens, toch heeft het geen positief effect bij mensen met maligne mesothe-
lioom. (dit proefschrift)
2. Alleen het verminderen van de microvaat dichtheid (MVD) is niet voldoende 
om de progressie vrije overleving te verbeteren bij mensen met maligne 
mesothelioom. (dit proefschrift)  
3. Patiënten met in de tumor een lage mRNA expressie van VEGFR3, een 
groeifactor die verantwoordelijk is voor lymfangiogenese, hebben de beste 
papieren voor een partiele respons op chemotherapie. (dit proefschrift)
4. De beste methode voor responsmeting bij het pleuraal mesothelioom blijft 
de modified RECIST methode. (dit proefschrift)
5. “If you have cancer and you are a mouse, we can take good care of you”, is 
nog steeds actueel. (Judah Folkman, 1998) 
6. De meest effectieve manier om op termijn de incidentie van mesothelioom 
te verlagen en daarmee veel leed te voorkomen, is strikte wereldwijde 
regelgeving ten aanzien van asbestverbod en het ontmantelen van asbest 
bevattende constructies.
7. Een mesothelioom is per definitie nooit oligo-gemetastaseerd.
8. De ongelijke verdeling van Covid-19 vaccins over de wereld is niet alleen 
moreel verwerpelijk, maar leidt uiteindelijk tot een nieuwe economische en 
epidemiologische crisis.
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General introduction and 
outline of the thesis




Malignant mesothelioma is a tumour arising from the mesothelial lining of the 
pleura, peritoneum, pericardium and tunica vaginalis. Pleural mesothelioma is the 
most common of these, accounting for approximately 90% of disease.
Asbestos, latency period, incidence and histologic subtypes
Malignant pleural mesothelioma (MPM) is a nearly invariably lethal tumour. The 
association with asbestos exposure is well established and this relation is found 
in more than 80% of cases. There are six types of asbestos that may be divided 
into two forms, serpentine and amphibole. The only serpentine type, chrysotile, 
also known as white asbestos, is made up of curled fibers and account for 
approximately 95% off all asbestos used worldwide. The amphibole group includes 
amosite, crocidolite, tremolite, anthophyllite and actinolite. Their straighter, 
needle-like, friable fibers distinguish them from chrysotile. Of the amphiboles, 
amosite (brown asbestos) and crocidolite (blue asbestos) had the most industrial 
usage. The World Health Organisation (WHO) concluded in 2006 that all types of 
asbestos cause cancer in humans. The latency of mesothelioma, that is the time 
elapsed between first exposure to asbestos and the diagnosis of the disease, 
is long. Latency periods of 20 to 45 years are reported. In the Netherlands the 
use of crocidolite was forbidden in 1978 and since 1993 the use of all asbestos 
was forbidden. This has influenced the incidence of mesothelioma, but the long 
latency period causes a delayed diminishment of the disease. In 1995 365 cases of 
mesothelioma were diagnosed and in 2018 this number grew to 625 cases. This is 
one of the highest incidence in Western Europe. The incidence rate of the last 5 
years in the Netherlands may suggest that the peak incidence has been reached.1 
The incidence reveals high regional variability due to clusters of disease around, 
for example asbestos cement industries and shipyards, where the incidence can 
reach up to 27/100,000 inhabitants, almost a tenfold compared to regions where 
such industries are not present (figure 1.1).
The WHO 2015 classifies MPM into three major histologic subtypes of prognostic 
importance: epithelioid, biphasic and sarcomatoid. Epithelioid mesothelioma 
is the most common type with the best prognosis, constituting 50–70% of all 
malignant mesothelioma. Sarcomatoid mesothelioma is the least common type 
of mesothelioma (10–15%). A further 20–40% of mesothelioma are classified 
as ‘biphasic’, a combination of the sarcomatoid and epithelioid types. Patients 
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with sarcomatoid or biphasic mesothelioma have shorter survival times. Overall, 
epithelioid mesothelioma patients typically survive one to two years, while 
sarcomatoid mesothelioma patients have an average survival of six months.
 
Figure 1.1: The incidence of MPM reveals high regional variability. 
Source: Sociale Verzekeringsbank.
Treatment modalities
MPM is notoriously refractory to different treatment modalities. Options are 
surgery, surgery in combination with chemotherapy and/or radiotherapy, or 
chemotherapy alone. All kind of biologicals and immunotherapy are under 
investigation.
Surgery
The role of surgery in the management of malignant mesothelioma remains 
controversial. Because of the incompleteness of the resection as single-modality 
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therapy, combinations of chemotherapy, surgery and radiation therapy were 
initiated as new treatment strategy to improve prognosis. Three prospective 
multicenter phase 2 trials of multimodality treatment including extrapleural 
pneumonectomy (EPP) showed disappointing results.2-4 In all these trials it was not 
only hard for patients to complete all three treatment modalities (in time), but 
results were also disappointing. The median overall survival (OS) was 16.8 to 19.8 
months, only a fraction longer than patients treated with palliative chemotherapy 
in that time. To investigate the effectiveness of EPP compared to palliative care in 
the management of MPM the Mesothelioma and Radical Surgery (MARS) trial was 
designed.5, 6 Patients received three cycles of chemotherapy and were then assigned 
to either EPP followed by hemi thoracic irradiation or to palliative care, which could 
include chemotherapy, radiotherapy and surgery (pleurodesis). The feasibility 
study of 50 randomised patients showed a better median and 1-year OS for the 
palliative care group than those treated with EPP. Despite all the shortcomings of 
the study, EPP became less popular after this trial. The observation that patients 
treated with lung sparing surgical procedures did better than those undergoing 
EPP supported the idea of combining extended pleurectomy decortication (P/D) 
with chemotherapy and or radiation. A pooled retrospective series of 663 patients 
with all stages MPM, demonstrated essentially no survival differences between 
P/D (median survival of 16 months) and EPP (12 months). This was despite the 
observation that the group undergoing P/D was negatively selected as considered 
to have a worse prognosis and to be no candidate for EPP. Local recurrence rate in 
this study was higher in de P/D group: 65% versus 33%.7 A retrospective analysis of 
the International Association for the Study of Lung Cancer Mesothelioma database 
of 3,101 patients of 15 centers worldwide showed in the EPP group a survival 
benefit of 40 months compared to 23 months for a P/D in stage I patients. All other 
stages showed similar outcomes. Patients undergoing curative intent- operations 
who received additional treatment (chemotherapy, radiation or both) had a better 
outcome with median survivals of 20 versus 11 months.8 A meta-analysis of seven 
relevant studies comparing outcomes of extended P/D (n=513) and EPP (n=632) in 
a multimodality setting demonstrated significantly lower perioperative mortality 
(2.9% versus 6.8%) and morbidity (27.9% versus 62%) for patients who underwent 
extended P/D. Median overall survival ranged between 13–29 months for extended 
P/D and 12–22 months for EPP, with a trend favoring extended P/D.9 These 
observations led to the question whether P/D as part of multimodality treatment 
further improves outcome. This will be investigated in the MARS-2 trial wherein 
P/D will be randomly assigned to standard induction chemotherapy.10 Furthermore 
The Lung Cancer Group of the European Organisation for Research and Treatment 
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of Cancer (EORTC) will conduct a randomised phase 2 trial in patients with early 
stage MPM randomizing between cisplatin pemetrexed followed by P/D or P/D 
followed by the same chemotherapy. This study (E1205) will evaluate whether 
immediate or deferred P/D in combination with chemotherapy is feasible and 
safe.11
In the preceding disquisition it is explained that surgery may have a place in the 
treatment of mesothelioma, but further studies need to confirm this hypothesis. 
Chemotherapy: pemetrexed and cisplatin
Currently, chemotherapy is regarded to be the best available treatment for patients 
with mesothelioma. Two large phase 3 studies have shown that the combination of 
cisplatin with an antifolate drug (pemetrexed or raltitrexed) significantly improves 
both response rate and median overall survival compared with cisplatin alone, with 
a survival benefit of 2.8 months in the first-line setting. Unfortunately, this is not a 
long lasting effect. Most patients’ disease progressed within the first 6 months and 
only 20% were alive at 2 years’ follow up.12, 13 Recently bevacizumab was added to 
standard first-line chemotherapy cisplatin and pemetrexed in a randomised phase 
3 trial (MAPS). The primary outcome overall survival was significantly longer in the 
group of patients that were randomised to the bevacizumab arm, 18.8 versus 16.1 
months (HR 0.77, p=0.01). Unfortunately, this was not enough to fulfil the required 
criteria for a general acceptance in the European countries. Therefore, this drug 
combination was not registered in the Netherlands as the new standard of care.14 
At this moment, the combination of pemetrexed and cisplatin is the only registered 
treatment for MPM. Since the implementation of this treatment in 2003, no other 
drugs have been approved for this indication. This means also that after progression 
on pemetrexed and cisplatin, no approved treatments are available. Accordingly, 
improvements of systemic therapies are needed urgently and in this thesis, the 
possibility of adding several antiangiogenic drugs to standard chemotherapy was 
explored.
Tumour angiogenesis
The ratio of tumour angiogenesis (the formation of new blood vessels) was based 
on the observation of Judah Folkman that growth of solid neoplasms is always 
accompanied by neovascularisation.15 He stated that the population of tumour cells 
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and the population of capillary endothelial cells within a neoplasm may constitute 
a highly integrated ecosystem. In this ecosystem, the mitotic index of the two 
cell populations may depend on each other. Tumour cells appear to stimulate 
endothelial-cell proliferation and endothelial cells may have an indirect effect over 
the rate of the tumour growth. The rapidity with which tumour implants are able 
to stimulate cell division in neighboring capillary endothelial cells was illustrated 
in the experiments of Wood. Tumour cells injected into the artery supplying the 
ear chamber of a rabbit were observed as they entered the capillaries, traversed 
the capillary wall and arrived in the extravascular space, where the cells formed a 
microscopic tumour nodule. However, only 18 hours after their arrival, endothelial 
cell regeneration and the formation of new capillary sprouts were observed to 
originate in neighboring post capillary venules.16 It has been shown in 1968 that 
new capillary sprouts are elicited, even if a tumour implant is enclosed in a Millipore 
filter chamber. In the laboratory vasoproliferative activity was consistently seen 
in hamster cheek pouch adjacent to tumour implants despite of the tumour and 
its stroma by a Millipore filter that prevents the passages of cells.17 These studies 
suggested that some diffusible message was released from tumour to nearby 
endothelial cells, these cells are then switched from a previously resting, non-
regenerating state to a rapidly dividing group of regenerating cells, capable of 
forming new capillary sprouts that can grow at the rate of 1 mm per day (figure 1.2). 
 
Figure 1.2: VEGF stimulates blood supply of the tumour.
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It has been shown that in the absence of neovascularisation, most solid tumours stop 
growing when they reach 2–3 mm in size and enter a dormant though viable state. 
When tumours are removed from this dormant state and placed in an environment 
that is highly vascularized, rapid neovascularisation will occur and is accompanied 
by rapid growth. Even when a proper vascularisation has been established, the 
efficiency of diffusion of nutrients diminishes with increasing distance from each 
capillary. 
Probably one of the major ‘diffusible messages’ that Folkman called Tumor-
Angiogenesis factor (TAF) turned out to be vascular endothelial growth factor 
(VEGF), the most powerful endothelial cell specific mitogen associated with 
neovascularisation. The major components of the VEGF family are VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, and placental growth factor (PlGF), as well as three receptor 
tyrosine kinases, VEGFR-1, VEGFR-2, and VEGFR-3. VEGF-A, usually referred to 
simply as VEGF, binds to endothelial cell VEGFRs 1 and 2. Binding to VEGFR-2 
sets in motion a number of intracellular signaling pathways that lead to multiple 
functions necessary for sprouting neoangiogenesis, including cell division, 
migration, vascular permeability, and promotion of cell survival. VEGFR-3 is largely 
restricted to lymphatic endothelial cells. The role of VEGF receptor 1 (VEGFR-1) 
is less clear. It binds VEGF with approximately 10 times the affinity of VEGFR-2 
binding, but its signal-transducing properties are extremely weak. It does not 
mediate an effective mitogenic signal in endothelial cells, but it does induce the 
release of vascular-bed specific growth factors. It may also act as a decoy receptor, 
that is able to regulate the activity of VEGF in a negative fashion in the vascular 
endothelium, by rendering this factor less available to VEGFR-2.18 
Several designations for the VEGF family have been reported. VEGFR-1 is also 
known as fms-related tyrosine kinase 1 or Flt-1; VEGFR-2 is also known as kinase 
insert domain receptor or KDR. VEGFR-3 as fms-related tyrosine kinase 4 or Flt-4.
There is evidence that suggests that neoangiogenesis can be an important 
determinant in the development and progression of mesothelioma. In preclinical 
models VEGF increased proliferation of mesothelioma and antibodies against VEGF 
and its receptor inhibited mesothelioma growth.19 In a mesothelioma population 
a two-to three fold higher serum levels of VEGF was observed, compared to other 
tumours or healthy volunteers, suggesting an autocrine effect of the tumour. 
Furthermore, MPM demonstrated a higher microvessel density (MVD) than other 
common tumours. In biopsies of patients with mesothelioma, a high MVD was 
independently related to poor survival, even if it was adjusted to other known 
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prognostic factors such as histological subtype and age.19, 20 These observations 
led to the exploration of several kinds of antiangiogenic drugs in mesothelioma 
that were used as a monotherapy or in combination with chemotherapy. 
Antiangiogenic drugs in MPM are the base of this thesis. We used the oral drug 
thalidomide in a randomised phase 3 switch-maintenance study and the oral drug 
axitinib in combination with cisplatin/pemetrexed in a phase 2 study as first-line 
therapy.
Thalidomide
The working mechanism of thalidomide is after all these years still not completely 
unraveled. Thalidomide consists of a racemic mixture of S(-) and R(+) enantiomers 
(isoforms). These are molecules with identical chemical composition that are mirror 
images of one another and that cannot be superimposed (figure 1.3). In nature, 
compounds often consist as enantiomers, although generally only one form is 
physiologically useful. In case of thalidomide, there seems to be a segregation of 
activities between these different forms. The S(-) enantiomer is associated with 
the teratogenic effects of thalidomide, whereas the R(+) isoform seems to be 
responsible for sedation. However, in humans this separation in function seems 
only to be theoretical, since they have a rapid interconversion of the two isomers. 






Thalidomide has a long history. It was manufactured and marketed by a German 
pharmaceutical company during the mid-1950s. It is a non-barbiturate drug with 
a sedative and anti-emetic activity. It rapidly became popular as a drug to counter 
the effects of morning sickness in pregnant women. It was withdrawn from the 
market in 1961 after reports that thalidomide was associated with birth defects, 
phocomelia, and neuropathy. Unfortunately, this withdrawal was too late to 
prevent the birth of approximately 10,000 babies with severe developmental 
deformities, which included the stunted limb development that is characteristic 
of ‘thalidomide babies’ (figure 1.4). In 1965 it became clear that thalidomide had 
immunomodulatory and anti-inflammatory properties following a serendipitous 
discovery, that patients with erythema nodosum leprosum (ENL) showed complete 
remission within a couple of weeks of thalidomide treatment. In 1991 it was 
discovered that the potent anti-inflammatory activity was at least partly explained 
by the fact that the drug inhibited the synthesis of tumour-necrosis factor-α (TNF-
α). This explained the effect in patients with ENL, as they have extremely high levels 
of TNF-α in their blood and dermatological lesions.21 In 1994, it was found that 
thalidomide inhibits angiogenesis. Folkman believed that the classical congenital 
defects caused by thalidomide, were caused by the inhibition of blood-vessel 
growth in the developing fetal limb bud. Using a rabbit cornea micro pocket assay, 
it was demonstrated that thalidomide could inhibit basic fibroblast growth factor 
(bFGF) induced angiogenesis.22 In 2009, researchers observed that thalidomide 
blocked the filopodial outgrowth of endothelial cells and that proliferation and 
migration and forming of vascular tubes was prevented.23 It was also shown that 
thalidomide was an effective treatment in patients with advanced and refractory 
multiple myeloma. Multiple myeloma is an incurable B-cell malignancy in which 
increased bone-marrow microvessel density is associated with poor prognostic 
outcome. Ten percent of patients had complete or near complete response 
and partial remission was achieved in 25% of patients. Decreased MVD in the 
responding patients supported the idea that angiogenesis is a therapeutic target 
in multiple myeloma.24 
All these findings resulted in a single arm phase 2 study in our institute in which 
40 patients with MPM were evaluable for efficacy. Twenty of them had received 
prior treatment. Twenty-seven percent of patients showed disease stabilization 
for more than 6 months, the primary endpoint.25 This work was the foundation of 
the randomised phase 3 switch maintenance study with thalidomide in 222 MPM 
patients described in this thesis.




Axitinib is an oral potent and ATP-competitive inhibitor of receptor tyrosine kinases 
of especially VEGFR-1, 2 and 3. It has a lower inhibitory activity against PDGFR and 
KIT. Axitinib dose-dependently inhibits endothelial cell proliferation, survival and 
three- dimensional tube formation in vitro. It rapidly blocks downstream signal 
transduction via the eNOS/AKT pathway that has been implicated in the pathologic 
angiogenesis and normal vascular homeostasis. In the development of axitinib, it 
has been shown, that in vivo the drug inhibits VEGFR-2 phosphorylation in retina of 
Sprague-Dawley rats, which translated into inhibition of angiogenesis and tumour 
growth regardless of initial tumour size. It also demonstrated a relatively short 
effect of the drug. Neoangiogenesis occurred as early as 1 day after withholding 
axitinib and full revascularisation occurred within 7 days. A second cycle of the 
drug resulted in the return of angiogenesis inhibition.26 In a phase 1 trial clinical 
activity was demonstrated. Partial response was documented in three patients, 
two of them with renal cell carcinoma and the third one with adenoid cystic 
carcinoma. Two NSCLC patients developed cavitations of lung lesions, indicating 
antiangiogenic effect. The recommended dose of axitinib was 5 mg twice daily, 
which has been the dose used in all subsequent trials.27 Axitinib is a well-tolerated 
drug, common side effects are hypertension, hand-foot syndrome and diarrhea. In 
several studies a correlation was shown between the development of hypertension 
after 4 weeks of therapy and the activity of the drug based on the objective 
response to treatment. One study showed that patients with a higher diastolic 
Figure 1.4: Baby with stunted limb development 
which is characteristic of ‘thalidomide babies’. 
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blood pressure (≥10 mmHg), compared to baseline had longer progression free 
survival (PFS), but this was not confirmed in all studies.28 Axitinib has been tested 
in combination with various chemotherapy regimens such as carboplatin, cisplatin, 
paclitaxel and gemcitabine and no increased toxicity or signs of drug interaction 
was seen. Axitinib has been successful in other solid tumours. In a phase 3 trial 
comparing the efficacy and safety of axitinib versus sorafenib as second-line 
treatment for metastatic renal cell carcinoma, patients who received axitinib had 
a longer PFS. These results established axitinib as a second-line treatment option 
in this patient group.29 A randomised phase 2 trial of gemcitabine with or without 
axitinib in advanced pancreatic cancer suggested increased overall survival in 
axitinib-treated patients, but the drug failed to confirm this in a randomised 
phase 3 study.30 The promising results of axitinib as a potent oral VEGF inhibitor 
and the fact that it was well tolerated in combination with chemotherapy lead to 
the randomised phase 2 study adding axitinib to pemetrexed-cisplatin in patients 
with malignant pleural mesothelioma, described in this thesis. The sequential 
thoracoscopies that were performed gave us the opportunity to compare clinical 
and translational outcomes.
Response Evaluation Criteria in Solid Tumors (RECIST)
In general, benefit in overall survival is the best way to investigate the potential of 
a new drug compared to standard of care. Unfortunately, this is a time consuming 
procedure and many patients are needed to find new relevant therapies. In an era of 
fast new drug development it is important to find quick answers in smaller studies. 
In this way, researchers can move forward with the most potential drugs. One way 
to perform such an evaluation is by using radiological response on CT scans. The 
ability to measure reproducibly tumour response and a correlation between tumour 
response and survival are crucial in this system. Conventional response criteria have 
always been difficult to apply to MPM due to its unique pattern of growth. The 
latest published RECIST criteria specify the use of unidimensional measurements, 
with partial response (PR) defined as a decrease of 30% in the sum of the longest 
diameter for all target lesions.31 However, MPM most commonly grows as a rind 
around the pleural surface, this makes the selection of measurement sites difficult 
because the longest diameter of a tumour mass is frequently that which follows 
the inner curve of the chest wall. Defining the limits of such a diameter is often 
problematical and interobserver variations, thus an unreliable outcome, may be 
the consequence. That is the reason why modified RECIST criteria, especially for 
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MPM patients, were developed. In this system, tumour thickness perpendicular 
to the chest wall or mediastinum is measured in two positions at three separate 
levels on transverse cuts of CT scan. The sum of the six measurements is defined as 
a pleural unidimensional measure. Nodal, subcutaneous and other bidimensionally 
measurable lesions were also measured unidimensionally as per the RECIST criteria 
and they were added to obtain the total tumour measurement. The definition of 
PR, stable disease and progressive disease were somewhat arbitrary and similar to 
the RECIST criteria: progressive disease (PD) is a summed measurement increase 
between scans larger than 20%, PR is a summed measurement decrease of 30% 
or more and stable disease is any measurement between -30% and +20%. The 
history of the RECIST classification criteria casts some doubt on the applicability 
of such criteria for classification of response in a disease so typically aspherical as 
mesothelioma. It has been investigated that other geometrical models, such as 
crescent or annulus, would more closely approximate the corresponding volume 
changes seen in tumours of spherical morphology if the definition of SD were 
broader.32 It appeared that the performance of the modified RECIST criteria could 
be improved by changing the response classification criteria to -64% and +50%, this 
way the optimal correlation between response and overall survival was achieved.33 
To validate these new response criteria they must be tested in an independent 
patient cohort to prove if they are useful in the assessment of clinical trials and 
routine patient care. This research is presented in this thesis.
The outline of this thesis 
As is made clear from the introduction MPM is a serious illness, without curative 
options and only one approved therapy: palliative chemotherapy, cisplatin and 
pemetrexed. This combination improves median overall survival with only 3 
months compared to cisplatin alone. Since preclinical data were promising for the 
use of antiangiogenic drugs in mesothelioma, 2 trials were designed to investigate 
the significance of these class of drugs in MPM: thalidomide and axitinib.
Chapter 2 is a systemic review that discusses second-line therapies in mesothe-
lioma. As was mentioned earlier, only the first-ine treatment of a pemetrexed 
containing doublet is standard of care. More than 30 trials are discussed. The 
results are presented according to the class of drugs: chemotherapy and targeted 




Chapter 3 shows the first multi-center randomised phase 3 study of switch 
maintenance therapy in mesothelioma. Thalidomide and active supportive care 
or active supportive care alone were given to patients with mesothelioma who 
did not progress on first-line treatment with a pemetrexed-containing therapy. 
Two-hundred and twenty-one patients were included in the primary analysis. A 
biomarker analysis was performed in a representative subset of patients. Primary 
outcome was time to progression.
Chapter 4 reports on a randomised phase 2 study adding the oral VEGF TKI 
axitinib to standard of care pemetrexed and cisplatin in the first-line setting. This 
single center trial was performed in the Netherlands Cancer Institute. Thirty-one 
patients were treated with pemetrexed and cisplatin and they were randomised 
to receive axitinib or no additional drug. Before start of treatment a thoracoscopy 
was performed for diagnosis and research purposes. After three courses of 
treatment, a second thoracoscopy took place for a palliative pleurectomy. During 
both procedures, biopsies were taken with the intention to combine clinical and 
translational outcomes.
Chapter 5 is a radiological study that was performed in cooperation with the 
University of Chicago. It describes de CT scans of 65 patients who participated 
in the above-mentioned randomised phase 3 study with thalidomide. Aim of the 
study was to find a better correlation between radiological response and survival 
using the modified RECIST criteria. What are the optimal cut-offs for progressive 
disease, stable disease and response?
Chapter 6 gives an up to date review of all the studies that were published in 
recent years, concerning inhibitors of angiogenesis in mesothelioma.
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After the implementation of standard first-line chemotherapy with platinum and 
antifolates in pleural mesothelioma, patients are confronted with a need for second-
line treatment at relapse or progression. We conducted a systematic review of the 
literature for the activity, effectiveness and toxicity of second-line treatment. The 
results are presented according to the class of drugs: chemotherapy and targeted or 
biological agent.




Malignant pleural mesothelioma (MPM) is a cancer of the surface mesothelium of 
the pleural cavity. Over 80% of mesothelioma patients have a history of previous 
intense occupational asbestos exposure. A causal relation has been repeatedly 
documented, although MPM can also result from very low levels of environmental 
exposure.1 The average latency of 40 to 45 years or more since the start of the 
exposure as found in studies with adequately long follow-up time explains the 
pattern of the observed mesothelioma incidence increases over the last decades 
with an estimated 43,000 annual deaths worldwide and why substantial decreases 
are not expected before 2020.2 Time trends indicate a slow shift of disease burden 
to countries consuming asbestos most recently,3 while incidence has peaked in 
most western industrialised countries after the ban of asbestos import and use 
in the eighties and nineties of last century.4 Other possible causes are ionizing 
radiation, endemic erionite exposure and chronic inflammation of the pleura.3
MPM has a poor prognosis: most patients will die of their disease within less 
than one year of diagnosis, if untreated. Among the reasons for this detrimental 
natural course are their insidious presentations in older patients with various 
comorbidities, its disease extension at diagnosis, a lack of curative treatments and 
a certain therapeutic nihilism among the medical profession.
With surgical resection being reserved for a small minority of patients, the only 
intervention with proven impact on outcome is palliative chemotherapy. One 
trial randomly compared first-line chemotherapy (either mitomycin, vinblastine, 
cisplatin (MVP) or vinorelbin) with active supportive care (ASC).5 Although no 
overall survival (OS) benefit or improvement in quality of life was seen in the 
intention-to-treat population, exploratory analyses suggested a survival advantage 
for vinorelbine with a 2 months’ survival benefit over ASC that approached 
significance, although these benefits were not seen for those patients who 
received MVP. Two randomised trials have further set the standard of care to a 
combination of cisplatin with an antifolate, either pemetrexed or raltitrexed.6, 7 A 
complete analysis of the efficacy and cost-effectiveness of first-line chemotherapy 
in MPM showed that both schedules were not different in terms of response 
rate (RR), time-to-progression (TTP) and OS.8 The implementation of novel first-
line chemotherapy has been associated with a population-based improvement in 
outcome over time.9 
With a median TTP of 5.5 months and 25% of patients refractory to first-line 
chemotherapy, increasing numbers of patients are now likely to be candidate 
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for second-line treatment. A systematic review concluded in 2010 that no 
cytostatic, immunomodulating or targeted drug had been validated in second-line 
chemotherapy and patients in a good performance status should be recommended 
to enter clinical trials.10 We updated this systematic review. 
Methods
The search for prospective published trials relative to the second-line treatment 
of malignant mesothelioma of pleural origin was performed by consulting the 
Medline and National Cancer Institute electronic databases. Search terms used 
included “mesothelioma” (medical subject heading (MeSH) with the subheading 
“drug therapy,” combined with “drug therapy” (MeSH), “chemotherapy” (MeSH), 
and “antineoplastic agents” (MeSH), and the text words “mesothelioma” and 
“second line”. Those terms were combined with the search terms for the following 
study designs and publication types: randomised controlled trials; controlled 
clinical trials; phase II (2) or III (3) clinical trials; and multicenter or comparative 
studies. 
In addition, conference proceedings of the annual American Society of Clinical 
Oncology (ASCO), the annual European Society Medical Oncology (ESMO) and the 
bi-annual World Lung Cancer Conference (WCLC) meetings for the years 2010–
2014 were searched for abstracts of relevant trials. 
The criteria of eligibility of the articles were the following: to focus only on 
patients with MPM; to be related to the study of single or combined cytotoxic and/
or targeted or biological agents, administered by systemic routes; to be published 
in the English language between January 2000 and July 2014; to be a prospective 
single or randomised phase 2 or phase 3 trial, with a minimum of 14 patients 
included. If less than 14 patients were included in a prospective phase 2 trial, 
the study could be considered as eligible if at least one objective response was 
observed when targeting a response rate of 20%, according to the Gehan’s design 
for phase 2 studies.11 We assumed that a chemotherapeutic agent had a clinical 
potentially useful activity in a trial if its objective response rate was at least 20% and 
we considered that a study was negative if the upper limit of the 95% confidence 
interval (CI) of the response rate was ≤20%. It was considered as positive if the 
lower limit of the 95% CI was >20% and as not conclusive but potentially positive if 
the upper limit of the 95% Cl was >20% but the lower limit <20%. For targeted and 
biological agents, we assumed that they had a clinical potentially useful activity if 
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the reported disease control rate (DCR = rate of OR + stable disease) was at least 
50% and we considered that a study was negative if the upper limit of the 95% CI 
of the response rate was ≤50%. It was considered as positive if the lower limit of 
the 95% CI was >50% and as not conclusive but potentially positive if the upper 
limit of the 95% Cl was >50% but the lower limit <50%.
Phase 2 trials with chemotherapy were grouped according to the following 
categories: single-agent chemotherapy, combination chemotherapy. Phase 2 trials 
with targeted and biological agents were grouped according to the predominant 
hallmark pathway involved: growth, angiogenesis, immunomodulation, invasion 
and metastasis, apoptosis.12
The response rates of the non-comparative trials were summed and averaged by 
category.
Results
Second-line chemotherapy in MPM 
We retrieved 86 articles matching the search criteria. Of these, 10 reported on 
phase 2 and phase 3 prospective clinical trials, of which one included less than 
14 patients. Another 6 articles were found by cross referencing, of which 2 in 
overlaying patient groups, 2 included less than 14 patients, 1 included 15 patients, 
but with results of first- and second-line therapy. A total of 10 articles reporting 
on 1,251 patients treated with second-line chemotherapy in MPM were eligible for 
this review (table 2.1).
In an unplanned subgroup analysis of patients treated in the pivotal registration 
phase 3 trial, Manegold et al. reported a significantly prolonged survival in the 
patients treated with post-study chemotherapy.13 Eighty-four patients (37.2%) 
of the cisplatin and pemetrexed arm and 105 patients (47.3%) from the cisplatin 
arm received post-study chemotherapy. The median time to start post-study 
chemotherapy after completion of first-line therapy was 3.6 months in the 
cisplatin/pemetrexed group and 0.7 months for the cisplatin group. According to 
that analysis, 62% of the study patients were treated with single agent post-study 
chemotherapy (48 from the pemetrexed/cisplatin group and 70 from the cisplatin 
group) and 38% received combination chemotherapy (36 from the cisplatin/
pemetrexed group and 35 from the cisplatin arm). Gemcitabine was mostly 
given as a single-agent. For patients with post-study chemotherapy MST was 
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15.3 months in the cisplatin/pemetrexed group and 12.2 months for the cisplatin 
group. These figures set the stage as they suggest a potential benefit for second-
line treatment. Only patients with complete data were included in this analysis, 
leading to compare populations with small numbers reducing the statistical power 
of the analysis. It must nevertheless be emphasised that these data have important 
limitations due to a selection bias. Patients receiving second-line chemotherapy 
are indeed a selected group in good clinical condition that often benefited of 
previous treatments.
Pemetrexed is of interest due to its role as first-line therapy. The international 
Expanded Access Program (EAP) was opened before its commercial availability in 
13 European countries and the US to provide both chemo-naïve and pre-treated 
patients access to pemetrexed, either as single agent therapy or in combination 
with platinum and this at the discretion of the investigator.14, 15 The results of 
EAP were reported in several publications, whereby results by treatment or 
treatment group were not always separately mentioned. In 396 pre-treated 
European patients, the overall response rate (ORR) with single agent pemetrexed 
was 12.1%, and the median time to progression (TTP) 4.9 months.14 The 1-year 
survival rate was 47.2%. Tolerability was good, suggested by the average amount 
of cycles of more than 6. Haematological toxicity was mild. No separate data on 
patients treated with the combination are reported. One hundred and eighty 
seven previously treated US patients were included: 91 received pemetrexed 
monotherapy, 96 received cisplatin/pemetrexed combination therapy.15 Previous 
regimens consisted of gemcitabine, cisplatin, carboplatin and paclitaxel. The 
patients receiving combination chemotherapy were on average younger and 
fitter at baseline and had a higher response rate to first-line therapy. This is also 
reflected by a higher number of treatment cycles administered to the combination 
group. Response data were available for 153 patients. ORR for the whole group 
was 19.6% with a RR of 32.5% for pemetrexed/cisplatin and 5.5% for pemetrexed 
alone. SD was achieved in 36.3% and 41.1% of patients, respectively. The median 
OS was 7.6 months with the combination therapy, 4.1 months with pemetrexed 
mono-therapy. Although the RR of 5.5% in the pemetrexed alone group is low, it is 
comparable to other single-agent regimens, as reported in a systematic review.16 
In this series a selection bias is present, as patients with co-morbidities and lower 
performance status were included, who might otherwise have been assigned to 
the treatment with combination platinum/pemetrexed. Another bias constitutes 
the fact that inclusion criteria for an EAP are less stringent than for a formal clinical 
trial.
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Sørensen et al. evaluated the efficacy of pemetrexed in second-line after platinum-
based chemotherapy in 39 patients previously treated with platinum-based 
regimens without pemetrexed.17 Twenty-eight Danish patients were treated with 
pemetrexed alone and 11 Norwegian patients with pemetrexed and carboplatin. 
Treatment with pemetrexed monotherapy gave a RR of 21% with a median TTP 
4.9 months (range 4–92) and OS 9.8 months (4–99 weeks), 1-year survival rate was 
36%. In the pemetrexed/carboplatin group the RR was 18%, the median TTP 7.4 
months and OS 9.1 months. The authors conclude that second-line treatment with 
single agent pemetrexed as in pemetrexed naive patients, is justified.
A large multicenter phase 3 study in advanced mesothelioma was designed to 
compare the efficacy and safety of pemetrexed and best supportive care (BSC).18 
Patients with relapsed MPM after first-line chemotherapy (excluding pemetrexed) 
were randomised between pemetrexed 500 mg/m2 every 21 days or BSC alone. 
Treatment was given for eight cycles or until progressive disease (PD). The primary 
endpoint of the study was OS. Secondary endpoints included RR, TTP, progression 
free survival (PFS), time to treatment failure and toxicity. Of the 243 patients 
included, the 143 patients receiving pemetrexed showed a PR in 18.7%. RR was 
19.2% with pemetrexed versus 1.7% in the BSC arm, respectively. The median TTP 
was 3.8 months versus 1.5 months. The median OS was not significantly different 
with 8.6 months versus 9.8 months, maybe due to the significant imbalance in 
post-study chemotherapy between the arms. This phase 3 trial demonstrated 
that pemetrexed in second-line delays disease progression for advanced MPM, 
reflected by the DCR of almost 60% in the pemetrexed arm and 19.2% in BSC arm. 
The chemotherapy was well tolerated and toxicities were mild. The BSC arm had a 
disproportionate number of patients who discontinued the study before response 
evaluation compared to the pemetrexed plus BSC arm. After study-discontinuation 
chemotherapy was allowed. Significantly more patients in the BSC arm (51.7%) 
received post-discontinuation chemotherapy than in the experimental arm (28.5%). 
Platinum, pemetrexed and gemcitabine were the most commonly used agents.
In a phase 2 open-label single-agent trial, the safety and efficacy of weekly 
vinorelbine was assessed.19 Patients with a good performance status and prognostic 
score according to EORTC were included. Sixteen percent of 63 pre-treated patients 
had a partial response to vinorelbine. Forty-three patients (68%) had a SD defined 
as no evidence for progression for 6 months. The OS was 9.6 months. Over half of 
the patients experienced a grade 3/4 toxicity. Median interval between the end 
of first-line chemotherapy and the start of weekly vinorelbine was 6 months. No 
separate analysis was performed in the patients pre-treated with pemetrexed.
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Picoplatin was designed to overcome resistance mechanisms. A phase 2, open-
label, non-comparative, multicenter study was designed to evaluate the activity 
and tolerability of picoplatin in 47 MPM pre-treated patients.20 The majority had 
advanced disease and 83% received prior platinum-based therapy. Of 43 evaluable 
patients no CR or PR was observed. This resulted in a RR of 12% of patients with 
a minor response, defined by reduction of lesion size ≥10% but <50%. SD was 
seen in 44%. The median TTP was 2.5 months, OS was 6.7 months. Picoplatin 
demonstrated a manageable tolerability profile. However, no complete or partial 
responses were seen. The activity of picoplatin is comparable to cisplatin in first-
line therapy and warrants no further investigation in MPM.
The combination gemcitabine and docetaxel was evaluated in 37 pre-treated 
patients.21 Docetaxel 80 mg/m2 and gemcitabine 1,000 mg/m2 were given on day 
1 and 14 of a 28-day cycle. Support of granulocyte colony-stimulating factor was 
allowed. The primary endpoint was RR and the secondary endpoints included 
TTP and OS. In 7 patients (18.9%) a PR was seen, SD in 23 patients (62.2%) and 
PD in 7 patients (18.9%). The median TTP was 7 months (range 5.8–8.2 months) 
with a median survival of 16.2 months (range 13–19.3 months). Haematologic 
toxicity occurred mostly with grade 3–4 neutropenia. However, the combination 
of gemcitabine and docetaxel is tolerable and safe and can be an option in pre-
treated patients. 
The combination of raltitrexed and oxaliplatin was investigated in 2 studies. Porta 
reported results of 14 patients who were treated with raltitrexed/oxaliplatin.22 
In this group, prior treatment mainly consisted of cisplatin and doxorubicin. No 
objective responses were seen and disease stabilization was observed in 4 patients. 
The 10 other patients were progressing, with a median time to progression of 1.9 
months. The median OS was 6.7 months. Although the combination of raltitrexed/
oxaliplatin has RRs in treatment naive patients of 30–35%, it failed to show any 
significant activity in second-line treatment of MPM.
Fizazi et al. performed an open-label, non-comparative, multicenter, phase 2 trial 
of 15 pre-treated patients and 55 chemo-naïve MPM.23 All pre-treated patients 
had prior cisplatin and a minimum of 2 chemotherapy regimens and were treated 
with raltitrexed/oxaliplatin. The RR was 20%, the median TTP 6.2 months, and the 
median OS 10.1 months. The combination showed responses even in the cisplatin-
resistant patients. The one-year OS was 40%. The toxicity was manageable; the 
most reported toxicity was asthenia. Grade 3 anaemia and neutropenia were 
observed only in 4.1% and 6.9% of the patients, respectively. 
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In vitro data suggested that valproic acid, a histone deacetylase inhibitor (HDACi), 
had a pro-apoptotic effect and synergised with doxorubicin to induce apoptosis 
in malignant mesothelioma cells.24 In a phase 2 trial, 45 patients pre-treated with 
at least one chemotherapy regimen including platinum derivatives, regardless 
response, received the combination of valproic acid and doxorubicin.25 The RR 
was 16%. The median PFS and the median OS was 2.5 months and 6.7 months, 
respectively. Two deaths ware related to toxicity, both in patients with poor PS. 
The authors commented that this combination seems to be an effective second-
line treatment in patients with good PS.
Second-line targeted and biological agents 
As an alternative to the cytotoxic treatment researchers have tested other 
pathways in MPM. From oral tyrosine kinase inhibitors to epigenetic compounds 
to immunotherapy (see table 2.2). 
Genetics
Recently, somatic and germ line genetic alterations have been identified that may 
lead to MPM itself or increase the susceptibility to asbestos carcinogenesis. MPM is 
particularly characterized by the loss of tumour suppressor genes, rather than gain 
of function mutations. The most frequently mutated tumour suppressor genes are 
discussed here and their possible implications for therapeutic interventions.26
Mutations in the neurofibromatosis type 2 gene (NF2) are found in 35–40% of 
MPM. The NF2 gene encodes a tumour suppressor gene merlin, a member of the 
band 4.1 family of cytoskeletal linker proteins. When the NF2 gene is mutated, non-
functional versions of merlin will be produced, being unable to function properly. 
Merlin mediates the contact dependent inhibition of cell proliferation in normal 
cells and interacts with more than 30 other intracellular proteins. Together with 
Focal Adhesion Kinase (FAK) it also inhibits the growth of cancer stem cells. Other 
key pathways are the mammalian target of rapamycin (mTOR); the Hippo pathway, 
which is important in cell proliferation, and extracellular signal-regulated kinase 
(ERK) pathways.26, 27
mTOR activity is up regulated in the absence of merlin, leading to increased cell 
proliferation. In the SWOG 0722 phase 2 trial the mTOR inhibitor everolimus was 
tested in 2nd or 3rd line. It did not meet its primary endpoint, an improvement of 4 
months in PFS from 30 to 50% (4 months PFS 34%).28 In view of the compensatory 
up regulation of PI3K seen with mTOR inhibition alone, dual inhibition of both 
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mTOR and PI3K, maybe a better approach. This was tested in a phase 1 study in 
patients with mesothelioma. An expansion cohort was created with the dual PI3K 
and mTOR inhibitor GDC-0980 with encouraging results.29
Further exploration of the mTOR signaling pathway involves focal adhesion kinase 
(FAK). This enzyme is involved in cell migration, adhesion and invasion. Merlin, the 
protein encoded by NF2, blocks FAK activation, so there is higher activation of FAK 
in tumours with merlin loss. VS-6063 is an inhibitor of FAK and appears to block the 
growth of mesothelioma cells in both xenografts and cell lines. This drug appears to 
work best in merlin deficient cell lines, but there still are signs of inhibition in wild 
type mesothelioma cell lines.30 These preclinical data led to the randomised phase 
2 maintenance study of VS6063 that is ongoing (NCT01870609), the estimated 
study completion date is December 2016. Primary endpoint will be PFS and OS. 
BRCA1-associated protein-1 (BAP1) is inactivated in around a quarter of MPM, 
although a number of different mutations have been identified.31 BAP1 has a 
role in DNA repair, control of gene expression through histone modification and 
enhancing progression through the G1-S checkpoint.32 The role of BAP1 in histone 
modification is of interest since it raises the possibility that histone deacetylase 
inhibitors (HDAC) may have activity in the disease. However the lack of clinical 
response in a large randomised phase 3 trial of the HDAC inhibitor vorinostat deny 
HDAC inhibitors to be an important strategy in tumours with BAP1 loss.33
Vascular targeted drugs
Tumour growth is strongly dependent upon angiogenesis and newly formed 
feeding vessels are required when the tumour size exceeds a diameter of 2 mm.34 
Mesothelioma cells often express vascular endothelial growth factor receptors 
(VEGFR) and produce growth factors like VEGF and basic fibroblast growth factor 
(bFGF).35 Patients with MPM express serum VEGF levels that are higher compared 
to other solid tumours or healthy individuals.36 High serum levels of VEGF and 
bFGF and microvessel density have been identified as negative prognostic factors 
for MPM.37, 38 
For these reasons many studies using antiangiogenic treatments in malignant 
mesothelioma have been published, but mostly with disappointing results. In 
a randomised phase 2 study investigating the effect of bevacizumab, a VEGF 
monoclonal antibody, in patients receiving cisplatin and gemcitabine, bevacizumab 
did not improve outcome.39 Although in this study an exploratory subset analysis 
showed improved survival for the bevacizumab chemotherapy regimen in patients 
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with low circulating levels of VEGF. Other phase 2 studies tested drugs with 
antiangiogenic properties like sorafenib,40 sunitinib,41 vatalanib42 and cediranib,43 
all of which reported low response rates and failed to show any anti tumour 
activity. One phase 2 study showed modest activity of cediranib after previous 
platinum-based therapy. Four patients (9%) in this single arm study showed a 
partial response, which did not meet the pre-specified 20% response rate of 
interest. However, there was marked shrinkage of bulky tumours in two of the four 
patient responders.44 This was the reason to proceed with a larger randomised 
phase 2 trial testing cediranib in combination with pemetrexed and cisplatin. A 
second phase 2 study of sunitinib as second-line therapy reported modest activity 
in progressing patients, but was unable to identify any serum biomarkers of 
response in angiogenesis pathways.45 A large randomised phase 3 study examined 
the oral antiangiogenic drug thalidomide in a switch maintenance setting. Patients 
with malignant mesothelioma who did not show progression after first-line 
chemotherapy were randomised to receive thalidomide or active supportive care 
until progression. The addition of thalidomide did not show any benefit in time to 
progression or overall survival.46
Immunomodulation and other mechanisms
The vascular disrupting agent NGR-hTNF is a combination of tumour necrosis factor 
(TNF), regulator of immune cells and inhibitor of tumourigenesis and asparagines-
glycine-arginine (NGR). It selectively targets TNF to an aminopeptidase N/CD13 
isoform overexpressed by endothelial cells in solid tumours. A single agent phase 
2 trial in 57 pretreated MPM patients showed a disease control rate of 46%, 
these patients experienced a median progression-free time of 4.4 months.47 
These results lead to a randomised phase 2 study NGR015 in which pemetrexed 
pretreated patients receive second-line chemotherapy vinorelbin or doxorubicin 
combined with either NGR-hTNF or placebo. The trial has completed its accrual 
and results are awaited (NCT01098266). Another incompleted study with NGR-
hTNF is is the randomised phase 2 trial NGR 019, with either weekly maintenance 
NGR-hTNF or placebo in patients not progressing after 6 cycles of pemetrexed 
containing therapy (NCT01358084).
BNC105P is a tubulin polymerisation inhibitor that selectively disrupts tumour 
vasculature and suppresses cancer cell proliferation. In a second-line phase 2 
study BNC105P was given until progression. Results were disappointing with a 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Platelet derived growth factor (PDGF) is a growth factor inducing mesothelial cell 
proliferation through the cell membrane receptor platelet derived growth factor 
receptor (PDGFR). A high serum PDGF in patients with MPM is an independent 
factor of poor prognosis. Imatinib and dasatinib are TKI inhibiting the PDGFR, but 
did not show clinical activity as single agents in phase 2 studies.49, 50
EGFR plays a role in cell proliferation, differentiation, migration, adhesion and 
survival. EGFR is overexpressed at protein level in more than 50–95% of the 
patients. Activating driver mutations of the tyrosine kinase residue, which 
translates the signal downstream and makes the tumour addicted to growth are 
rare in MPM.51 The EGFR TKI erlotinib and the combination of erlotinib and the 
chimeric mouse-human antibody targeting the extracellular domain of EGFR, 
cetuximab were studied in 2 phase 2 studies. Results were disappointing with no 
patients achieving a partial response.52, 53
The anti-cytotoxic T lymphocyte antigen 4 (CTLA4) specific monoclonal antibody 
tremelimumab is a new class of immunomodulatory monoclonal antibody. It 
targets the regulatory molecules expressed on immune cells to enhance the anti-
tumour activity of T-cells. In a single arm phase 2 study, twenty-nine patients were 
enrolled with unresectable MPM with progressive disease after first-line platinum-
based regimen.54 Although the study did not meet its primary endpoint, it did show 
encouraging clinical activity. Disease control was observed in 9 patients (31%) with 
a median progression free survival of 6.2 months and median overall survival of 
10.7 months. Two patients (7%) had durable partial responses, respectively 6 and 
18 months. Another phase 2 study in which also 29 patients were treated with 
tremelimumab 10 mg/kg every 4 weeks showed similar results.55 A randomised, 
double blind, placebo controlled, phase 2 study is currently evaluating 
tremelimumab with the primary objective of demonstrating a 50% improvement 
in overall survival from 7 to 10.5 months (NCT01843374). After a recent interim 
analysis the accrual target was increased to 542 patients.
A checkpoint inhibitor, pembrolizumab, was tested as single agent in a phase 1/2 
study and reported in abstract.56 In 25 patients out of 38 patients with positive 
staining for PD-L1, pembrolizumab treatment (10 mg/kg q2wk) resulted in a 
ORR of 20% and 72% had control of the disease. Ten patients could be treated 
for over 9 months with low toxicity. Only 1 grade 3 toxicity for ALT and 1 for 
thrombocytopenia were observed. These results have led to a randomised phase 2 
study (NCT02399371) currently open for recruitment in second line.
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Mesothelin is an antigen, which is highly expressed on certain tumour cells like 
mesothelioma, ovarian and pancreatic carcinoma. In normal tissues its expression 
is limited to mesothelial cells lining the pleura, the peritoneum and pericardium.57, 58 
Mesothelin has been used to target MPM in different ways. SS1P is a recombinant 
immunotoxin consisting of an anti-mesothelin variable fragment linked to PE38, a 
portion of Pseudomonas exotoxin A. In the preclinical setting it has shown to be 
cytotoxic to mesothelin expressing cell lines.59 In the first clinical trials, the vast 
majority of treated patients developed antibodies against SS1P after only one cycle 
of treatment, precluding its continued use as a therapeutic agent. To overcome 
this problem, patients were pretreated with pentostatin and cyclophosfamide; 
chemotherapeutic agents that specifically deplete lymphocytes, thereby 
preventing the formation of antitoxin antibodies. This resulted in remarkable 
improved clinical outcomes. Of 10 patients with chemotherapy-refractory 
mesothelioma, 3 had a major tumour regression, with 2 ongoing at 15 months, 
and to respond to chemotherapy after discontinuing immunotoxin therapy in an 
unexpected way.60 The development of anti-pseudomonas antibodies have urged 
the researchers to develop a second-generation immunotoxin where the B-cell 
activating sites of the molecule have been replaced by less immunogenic residues. 
Bortezomib, a proteosome inhibitor, was tested as single agent in a multicenter 
study.61 Of the 23 patients included, only 1 patient responded (4.8%). The PFS was 
2.1 month with an OS of 5.8 months. Single agent therapy showed insufficient 
activity to continue research in unselected patients.
Conclusions
The development of effective treatments in MPM has been notoriously slow and 
unsuccessful. It was until 2003 when two randomised phase 3 studies showed that 
the combination of a platin compound and anti-folate improved PFS, OS and did 
not impair the quality of life. Unfortunately most patients’ disease progressed 
within the first 6 months. This leads to new studies in MPM in the second-line 
setting. The classical, chemotherapy compounds tested, did not really show any 
improvement and more emphasis was given to drugs that might stabilise the 
disease with manageable toxicity. Only one phase 3 study was reported where 
pemetrexed was compared to BSC. The final analysis did not show any benefit 
in OS but an improvement in disease control was observed. Crossover from the 
BSC arm to pemetrexed probably accounts for this observation. Other single 
agent drugs did not impress the scientific community with activity or tolerability. 
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Only a limited number of randomised phase 2 studies with combination therapy 
have been examined. They focused mostly on a combination with pemetrexed and 
platin compound. Although acceptable in patients with a good PS, none of these 
have been adopted as standard therapy in second line.
The following conclusions regarding second-line chemotherapy in MPM can be 
drawn:
• Single agent vinorelbine or pemetrexed are acceptable 2nd line agents 
for patients relapsing after a first-line platinum combination depending 
on its association with pemetrexed or not.
• The low reported activity of the drugs in second-line warrants referral of 
fit patients to participate in clinical trials.11 The latter should preferably 
consist of randomised phase 2 trials, whereby patients will be randomly 
allocated to either the new single agent or one of the single agents with 
documented activity.
With the identification of driver mutations in lung cancer, high expectations were 
also set for mesothelioma. Unfortunately the TKI’s did not perform as expected. 
While high levels of EGFR expression were observed in most MPM samples, no 
mutations in exon 19 or deletions in exon 21 were observed. Pathways of interest 
in MPM have been narrowed down to mTOR and PI3CA, while others have been 
tested without a clear success. New approaches like the use of immune checkpoint 
inhibi tors and immunotoxins seem to be more effective. Studies in maintenance 
setting or in second or third line are now in place and seem to be very active in a 
subset of patients. The problem remains how to select patients suitable for this 
kind of therapy. 
It is clear that the new developments in immunotherapy and pathway modulation 
will open new perspectives for treatment. Since single agent treatment is not 
expected to lead to long-term disease control, combination treatments must be 
tested. This must be done with care and proper planning since the number of 
patients with MPM who are suitable candidates for studies is relatively small.
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Background: Standard chemotherapy does not lead to long-term survival in patients 
with malignant pleural mesothelioma. Malignant pleural mesothelioma is strongly 
dependent on vasculature with high vessel counts and high concentrations of serum 
vascular growth factors. Thalidomide has shown antiangiogenic activity, and we 
hypothesised that its use in the maintenance setting, could improve outcome.
Methods: In this open-label, multicenter, randomised phase 3 study, eligible 
patients had proven malignant pleural or peritoneal mesothelioma and had received 
a minimum of four cycles of first-line treatment containing at least pemetrexed, 
with or without cisplatin or carboplatin, and had not progressed on this treatment. 
Patients were randomly assigned (in a 1:1 ratio, stratified by previous, first-line 
chemotherapy, histologic subtype and recruiting hospital) to receive thalidomide 200 
mg/day (including a 2 week run in of 100 mg per day) plus active supportive care or 
active supportive care alone until disease progression. Thalidomide was given for a 
maximum of 1 year or until unacceptable toxicity. The primary endpoint was time to 
progression. The primary analyses were by intention to treat. The study is registered, 
ISRCTN13632914.
Findings: Between May 11, 2004, and December 23, 2009, we randomly assigned 
222 patients, 111 in each group (one patient on active supportive care later 
withdrew consent and was excluded from analyses). At the time of this final analysis, 
median follow-up was 33.1 months (IQR 22.3–66.8), and physician-reported disease 
progression had occurred in 104 patients in the thalidomide group and 107 in the 
active supportive care group; 92 patients in the thalidomide group and 93 in the active 
supportive care group had died. Median time to progression in the thalidomide group 
was 3.6 months (95% CI 3.2–4.1) compared with 3.5 months (2.3–4.8) in the active 
supportive care group (hazard ratio 0.95, 95% CI 0.73–1.20, p=0.72). 43 (39%) grade 3 
or 4 adverse events were reported in the thalidomide group and 31 (28%) in the active 
supportive care group; neurosensory events were reported by two (2%) patients on 
thalidomide and none on active supportive care, cardiac events by two (2%) patients 
on thalidomide and three (3%) on active supportive care, and thromboembolic events 
by three (3%) patients on thalidomide and none on active supportive care.
Interpretation: No benefit was noted in time to progression with the addition of 
thalidomide maintenance to first-line chemotherapy. Different treatment strategies 
are needed to improve outcomes in patients with malignant mesothelioma.
Funding: Dutch Cancer Society (KWF), Eli Lilly, NSW Dust Disease Compensation 
Board, University of Sydney and Cancer Australia.




Malignant mesothelioma is invariably a lethal tumour of the pleura or peritoneum. 
It is one of the fatal diseases caused by exposure to asbestos fibre, and long-term 
survivors are rare. The incidence is fairly low, varying from two to 30 cases per 
100,000 population worldwide. Most patients are older than 70 years, a reflection 
of the latency period of 30–50 years after asbestos exposure.1 Although malignant 
pleural mesothelioma has a low incidence, the sociomedical implications of this 
asbestos-related disease are huge and the growing incidence in the developing 
world is alarming. 
Mesothelioma is notoriously refractory to different treatment modalities and 
currently chemotherapy is regarded to be the best available treatment. Two large 
phase 3 studies have shown that the combination of cisplatin with an antifolate 
(pemetrexed or raltitrexed) significantly improves both response rate and median 
overall survival compared with cisplatin alone, with a survival benefit of 2.8 months 
in the first-line setting.2-3 Although the response rates in first-line treatment were 
substantial (41 and 24%, respectively), most patients’ disease progressed within 
the first 6 months and only 20% were alive at 2-years’ follow-up, indicating that 
improvements are urgently needed.
An important target in cancer therapy is the tumour vasculature. Tumour growth 
is strongly dependent on angiogenesis and new feeding vessels are needed when 
the tumour size exceeds a 2mm diameter.4 Mesothelioma cells often express VEGF 
and to some extent basic fibroblast growth factor (bFGF).5-6 Additionally, patients 
with malignant pleural mesothelioma express serum VEGF concentrations that 
are higher than with other solid tumours or healthy individuals.7 High serum 
concentrations of VEGF and bFGF and microvessel density have been identified as 
negative prognostic factors for MPM.8-9
One drug that has shown antiangiogenetic activity and immunomodulation by 
inducing apoptosis of established new vasculature is thalidomide. Thalidomide has 
an excellent bioavailability after oral administration and has shown a pronounced 
antitumour effect in haematological malignancies. The effect in solid tumours is 
limited.10-12 It can be given for extended periods with tolerable side-effects. Apart 
from the mutilating focomelia during gestation, side-effects such as sedation 
and constipation occur frequently. Peripheral neuropathy is less frequent but is 
regarded as another important side-effect.13-14 
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We undertook previously a phase 2 study in patients with malignant pleural 
mesothelioma, in which disease stabilisation of 6 months or longer was observed 
in 28% of patients who received single agent thalidomide at progression.15 On the 
basis of these results, we undertook a randomised phase 3 study in patients with 
malignant pleural mesothelioma who did not progress after first-line cytotoxic 
treatment. We hypothesised that these patients might benefit from switch 
maintenance treatment with thalidomide. Switch maintenance is defined as the 




In this open-label multicenter phase 3 study, patients with unresectable malignant 
pleural or peritoneal mesothelioma who had completed first-line chemotherapy 
were randomly assigned to receive either maintenance thalidomide combined 
with active supportive care or active supportive care alone. Active supportive 
care was defined, in all participating centres, as proper analgesia, appropriate 
management of pleural effusions, use of palliative oxygen when indicated, 
attention to psychosocial needs, and allied health referrals—e.g., physiotherapy, 
when needed. The study was approved by the local IRBs and all patients provided 
a written informed consent.
Patients
Eligible patients had proven malignant pleural or peritoneal mesothelioma and 
did not show progression after first-line treatment containing at least pemetrexed 
(500 mg/m²), with or without cisplatin (75 mg/m²) or carboplatin (area under the 
curve 5), repeated every 3 weeks and with a minimum of four cycles of therapy. 
An expert pathology panel confirmed the diagnosis in all patients. The presence 
of a measurable lesion on CT scan was not a prerequisite. Other eligibility criteria 
were a WHO performance status of 2 or less and adequate bone marrow reserve, 
hepatic, and renal function. Key exclusion criteria were resectable mesothelioma 
as part of a multimodality trial, pre-existing grade 2 or higher (sensory) neuropathy, 
pregnancy or lactation, severe cardiac, pulmonary, metabolic, or other serious 
comorbid conditions, and life expectancy less than 3 months. Patients were 
required to be registered and to start treatment with thalidomide within 10 weeks 
after the end of the first-line chemotherapy.
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Randomisation and masking 
The randomisation schedule was generated centrally at the Netherlands Cancer 
Institute, Amsterdam, The Netherlands. TENALEA software (version 2.2) was used 
to assign patients to groups in a 1:1 ratio. Allocation to treatment groups was 
based on the minimisation method. Groups were stratified by recruiting hospital, 
pathology (epithelial vs other), and previous chemotherapy (platinum agent and 
pemetrexed vs pemetrexed alone). Treatment assignment was not masked.
Procedures
The initial dose of thalidomide was 100 mg per day (one tablet) to be taken before 
bedtime for 2 weeks. In the absence of side-effects after 2 weeks, the dose was 
increased to 200 mg per day. Patients who reported drowsiness or unacceptable 
side-effects could have a subsequent dose reduction to 100 mg per day when 
supportive care measures were inadequate. In case of neuropathy, a neurological 
consultation was required and the dose was withheld until improvement to grade 
1. When applicable, a dose reduction from 200 mg to 100 mg was allowed under 
strict neurological follow-up. No dose reductions to less than 100 mg per day were 
permitted. In the event of lack of improvement of the neurological symptoms, 
thalidomide was discontinued. For toxicity and disease evaluation, patients in both 
treatment groups were reviewed clinically every 4 weeks at the investigational site 
and a CT scan of the thorax or abdomen, or both, and laboratory and pulmonary 
function testing was done every 8 weeks. Thalidomide was to be given until disease 
progression for a maximum of 1 year.
Blood samples for the measurement of biomarkers16–18 were drawn from a 
subset of patients at baseline. After centrifuging, serum was stored at -30°C until 
measurement. Serum samples were collected in one institution (Netherlands 
Cancer Institute) during this study. VEGF, bFGF, and interleukin 6 concentrations 
were measured by means of ELISA assays (R&D Systems, Minneapolis, MN, USA). 
Serum cytokeratin fragment 21.1 (CYFRA 21.1) concentrations were measured 
on the Modular Analytics E170, an immunoassay analyser (Roche Diagnostics, 
Mannheim, Germany). Soluble mesothelin-related peptides (SMRP) concentrations 
were measured with the MESOMARK assay, using an ELISA format (Fujirebio 
Diagnostics, Malvern, PA, USA).
The primary objective of the study was to assess the effect of thalidomide on time 
to progression. Disease progression was defined as the occurrence of a new lesion, 
growth of a known pleural or peritoneal lesion of more than 20% of baseline (or by 
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5mm or more for lesions smaller than 1 cm), at the time of discontinuation because 
of toxicity or after 1 year of use. All CT scans were centrally reviewed (WAB and 
PB). Secondary objectives were overall survival and toxicity. Adverse events were 
graded according to the Common Terminology Criteria for Adverse Events (version 
3.0).
Statistical analysis
Without further treatment, patients are expected to progress within 5 months.2,3 
To detect an improvement of 50% in median time to progression (33% decrease 
in the hazard rate of progression), with 80% power using a two-sided logrank test 
(α=0.05), 190 events were needed. 
All analyses were by intention to treat. Time to progression and overall survival 
were assessed with logrank tests, and Cox proportional hazards models adjusting 
for the pathology and previous chemotherapy stratification factors. The 
proportional hazards assumption was tested with scaled Schoenfeld residuals. 
Time to progression was calculated as the time from randomisation until 
progression (including death due to malignant pleural mesothelioma). In the 
absence of progression, patients were censored at last contact or death without 
evidence of progressive disease. Overall survival was calculated as the time from 
randomisation until death of any cause, with patients alive at time of analysis being 
censored at the date of last contact. An additional post-hoc landmark analysis at 
week 4 was done, testing for a difference in time to progression between patients 
who received the per-protocol dose of thalidomide with those who had received 
less. In particular, the first group was defined as those who had an average daily 
dose intensity equal to or above 150 mg per day; and the second group defined as 
patients who had received an average lower than 150 mg per day. Only patients 
who were alive without progression at 4 weeks after randomisation were included 
in this analysis. The Kaplan-Meier technique was used to present survival curves 
and forest plots used to present the effect of treatment within subgroups. Fisher’s 
exact tests were used to assess the association between treatment and response. 
All analyses were done with the R statistical software (version 2.15.2), and all tests 
were two-sided with significance taken at 0.05. 
In the biomarker analysis, associations between the five markers were assessed 
with Spearman’s correlations. Unadjusted (univariable) and adjusted (covariates 
were age, sex, and treatment group) Cox proportional hazard models were used 
to assess the prognostic value of the five markers. The comparison of patient 
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demographic characteristics for the subgroups with and without biomarker samples 
was done with Fisher exact tests and Mann-Whitney-Wilcox tests as appropriate. 
Predictive value was assessed similarly with the inclusion of treatment group 
and the pairwise interaction between treatment and each marker. Martingale 
residuals were used to determine appropriate variate transformations to ensure 
linearity. Two Lasso (L1 penalised) Cox regression models were used to establish 
the predictive and prognostic value of the five markers in a multivariable setting. 
The optimum penalty parameter was determined with leave-one-out likelihood 
cross-validation. In the multivariable analyses, missing biomarker data were 
imputed using the cohort median. A sensitivity analysis was done in which only 
complete cases were included. The Kaplan-Meier method was used to present the 
associations between markers and survival, with the markers being dichotomised 
at the upper normal limit of a healthy population. 
This study is registered, ISRCTN13632914.
Role of the funding source
The study sponsors had no role in the study design, data collection, analysis, 
interpretation, writing, or the decision to submit for publication. WAB, ADV and PB 
had access to the raw data. The corresponding author had full access to all study 
data and final responsibility for the decision to submit for publication.
Results
Between May 11, 2004, and Dec 23, 2009, 222 patients were enrolled in eight 
Dutch and four Australian centres, 111 patients in each group (figure 3.1). One 
patient on active supportive care withdrew consent after randomisation and was 
excluded from analysis. The baseline characteristics of the patients were balanced 
between the two groups (table 3.1).
At the time of analysis, physician-reported disease progression had occurred in 104 
patients in the thalidomide group and in 107 patients in the active supportive care 
group. 185 patients had died: 92 patients in the thalidomide group (two of whom 
died without evidence of progression) and 93 in the active supportive care group. 
Median follow-up was 33.1 months (IQR 22.3–66.8). Median time to progression in 
the thalidomide group was 3.6 months (95% CI 3.2–4.1) compared with 3.5 months 




Figure 3.1: Trial profile.
Median overall survival was 10.6 months (95% CI 8.1–13.6) in the thalidomide 
group and 12.9 months (10.4–16.4) in the active supportive care group (HR 1.2, 
95% CI 0.9–1.6, p=0.21). Response to previous treatment (partial response or 
stable disease) was not prognostic for either time to progression or overall survival 
(data not shown). Figure 3.2 shows Kaplan-Meier plots for time to progression and 
overall survival and figure 3.3 shows forest plots. The week 4 landmark analysis of 
patients treated with thalidomide indicated no detectable differences in time to 
progression between those who had received 150 mg per day or more (n=74) as 
opposed to those who had received less (n=35; data not shown).
The median duration of treatment with thalidomide was 12.3 weeks (range 0–135, 
IQR 8.1–23.4). Seven (6%) patients chose to continue with treatment for more than 
1 year. Ten (9%) patients did not reach a dose of 200 g. The median average weekly 
dose was 1,202 mg (IQR 860–1,313). 18 (16%) patients discontinued treatment 
because of adverse events, and 79 (71%) patients did not require a dose reduction.
In general, the drug was well tolerated and no unexpected side-effects or treatment-
related grade 5 events were reported. Adverse events of any grade were reported 
by 106 patients on thalidomide and 89 patients on active supportive care. 43 (39%) 
patients in the thalidomide group and 31 (28%) patients in the active supportive 
care group had grade 3 or 4 adverse events, but there was no evidence for a 
difference for the individual adverse event categories. Most symptoms reported 
in the thalidomide group were judged unlikely to be related to the study drug. 
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In this open-label multicentre phase 3 study, patients 
with unresectable malignant pleural or peritoneal 
111 randomly assigned to thalidomide 111 randomly assigned to supportive care
222 patients registered
1 withdrew consent
111 included in primary analysis 110 included in primary analysis
77 no serum sample  71 no serum sample
34 included in biomarker analysis 39 included in biomarker analysis
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Only 23 (21%) patients had grade 3 or higher adverse events that were deemed 
to be related to treatment. Table 3.2 shows grade 3 or 4 adverse events deemed 
likely to be related to the study drug; constipation, neurosensory problems, and 
thromboembolism only occurred in the thalidomide group in two (2%), two (2%), 
and three (3%) patients, respectively. Fatigue and cardiac events were reported 
in a small number of patients in both groups. Haematological toxicities also did 
not differ between groups. Grade 2 neurotoxicity was seen in 20 (18%) patients 
treated with thalidomide versus no patients in the active supportive care group. 
Grade 2 constipation was reported for ten (9%) patients on thalidomide and two 
(2%) on active supportive care. Grade 2 thromboembolism was not reported for 







Variable No. % No. % No. %
Age, years
Median 64 64 64
Range 45–82 41–78 41–82
Sex
Male 92 83 95 86 187 85
Female 19 17 15 14 34 15
ECOG PS
0 38 34 46 42 84 38
1 69 62 62 56 131 59
2 4 4 2 2 6 3
TNM stage
1 17 15 12 11 29 13
2 25 23 28 25 53 24
3 47 42 45 41 92 42
4 16 14 20 18 36 16
Unknown 6 5 5 5 11 5
Pathology
Epithelial 96 86 94 85 190 86
Other 15 14 16 15 31 14
Prior treatment
Pemetrexed 4 4 3 3 7 3
Pemetrexed + Platinum 107 96 107 97 214 97
Response to first-line Pemetrexed therapy
CR 1 1 5 5 6 3
PR 39 35 34 31 73 33
SD 71 64 71 65 142 64
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neuropathy, a neurological consultation was required and 
the dose was withheld until improvement to grade 1. 
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reductions to less than 100 mg per day were permitted. In 
the event of lack of improvement of the neurological 
symptoms, thalidomide was discontinued. For toxicity 
and disease evaluation, patients in both treatment groups 
were reviewed clinically every 4 weeks at the investigational 
site and a CT scan of the thorax or abdomen, or both, and 
laboratory and pulmonary func tion testing was done 
every 8 weeks. Thalidomide was to be given until disease 
progression for a maximum of 1 year. 
Blood samples for the measurement of biomarkers16–18 
were drawn from a subset of patients at baseline. After 
centrifuging, serum was stored at –30°C until measure-
ment. Serum samples were collected in one institution 
(Netherlands Cancer Institute) during this study. VEGF, 
bFGF, and interleukin 6 concentrations were measured 
by means of ELISA assays (R&D Systems, Minneapolis, 
MN, USA). Serum cytokeratin fragment 21.1 (CYFRA 
21.1) concentrations were measured on the Modular 
Analytics E170, an immunoassay analyser (Roche Diag-
nostics, Mannheim, Germany). Soluble mesothelin-re-
lated peptides (SMRP) concentrations were measured 
with the MESOMARK assay, using an ELISA format 
(Fujirebio Diagnostics, Malvern, PA, USA).
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cardiac, pulmonary, etabolic, or other ser ous comorbid 
conditions, and life xp ctancy l ss than 3 months. 
Patients were r quired to be registered and to start 
treatment w th thalidomide wi in 10 w eks after the end 
of th  first-line chemotherapy.
Randomisation and masking
Th  randomisation schedule was generated centrally 
at the Netherlands Cancer Institute, Amsterdam, The 
Netherlands. TENALEA software (version 2.2) was used 
to assign patients to groups in  1:1 rat o. Allocation to 
treatment groups was based on the min misation method. 
Groups were stratifi d by recru ting hospital, pathology 
(epitheli l vs other), and previous chemotherapy 
(platinum age t and p metrexed vs pe trexed alone). 
Treatment assignment was not ma ked.
Procedures
The initial dose of thalidomide was 100 mg per day (one 
tablet) to be tak n before bedtime for 2 weeks. In the 
absence of side-eff ects after 2 eks, the dose was 
increased to 200 mg per day. Patients who reported 
dr wsiness or un cceptable side-eff ects could have a 
subsequent dose reduction to 10 mg per day when 
supportive care measures were inadequate. In case of 
neuropathy, a neurological c ns ltation was required and 
the dose was withheld until impr v ment to grade 1. 
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Figure 2: Kaplan-Meier plots for time to progression (A) and overall survival (B)
HR=hazard ratio.
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Figure 3.3: Subgroup analysis of the primary endpoint time to progression (A) and overall survival 
(B).
A subset analysis was performed that may suggest that in older patients thalidomide resulted in higher 
mortality rates, however the age-treatment interaction was not significant (p=0.15) (figure 3.3B). This 
may be an indication for caution in treating the elderly with thalidomide in other diseases. CR=complete 

















<65 55/58 58/59  0.8  ( 0.5- 1.4 )
65+ 49/53 49/51  1.1  ( 0.7- 1.9 )
(0) (0)
Tumor stage
1-2 61/65 66/67  1.0  ( 0.6- 1.6 )
3-4 38/40 37/39  0.9  ( 0.5- 1.7 )
(6) (4)
Pathology
Epithelial 89/96 91/94  1.0  ( 0.7- 1.5 )
Other 15/15 16/16  0.8  ( 0.3- 2.2 )
(0) (0)
Response to 1st line
CR/PR 36/40 38/39  0.9  ( 0.5- 1.6 )
SD 68/71 69/71  1.0  ( 0.6- 1.5 )
(0) (0)
IL6
<5.84 7/7 11/11  1.1  ( 0.3- 4.0 )
>5.84 24/27 26/28  0.7  ( 0.3- 1.4 )
(77) (71)
Overall 104/111 107/110  1.0  ( 0.7 -  1.2 )

















<65 47/58 54/59  1.0  ( 0.6- 1.7 )
65+ 45/53 39/51  1.5  ( 0.9- 2.7 )
(0) (0)
Tumor stage
1-2 58/65 58/67  1.3  ( 0.8- 2.0 )
3-4 30/40 33/39  1.1  ( 0.6- 2.1 )
(6) (4)
Pathology
Epithelial 79/96 78/94  1.3  ( 0.9- 2.0 )
Other 13/15 15/16  0.6  ( 0.2- 1.5 )
(0) (0)
Response to 1st line
CR/PR 34/40 35/39  1.4  ( 0.7- 2.6 )
SD 58/71 58/71  1.1  ( 0.7- 1.8 )
(0) (0)
IL6
<5.84 5/7 8/11  1.7  ( 0.4- 7.8 )
>5.84 22/27 24/28  0.8  ( 0.4- 1.6 )
(77) (71)
Overall 92/111 93/110  1.2  ( 0.9 -  1.6 )





any patient. In the thalidomide group, 18 (16%) patients went off study because 
of adverse events, primarily neuropathy and fatigue.
Serum samples for VEGF, bFGF, interleukin 6, CYFRA 21.1, and SMRP analyses were 
collected prospectively in 73 patients. There was good agreement between the 
demographic profiles with and without biomarker samples. The main difference 
between the populations occurred in TNM stage, with a smaller proportion of 
late stage tumours in the marker cohort (table 3.3). Within the marker subgroup, 
demographic characteristics were well balanced between thalidomide-treated 
patients and those not treated. There was moderate correlation between the 
markers VEGF, interleukin 6, and bFGF (Spearman correlations, ρ=0.30–0.45), 
with CYFRA 21.1 and SMRP more strongly correlated (=0.60). No other pairwise 
correlations were significant.
Martingale residuals indicated that logarithmic transformations of the biomarkers 
resulted in linear associations with the log-hazard. After transformation, interleukin 
6 was very strongly associated with survival (p=0.00096), and this association was 
unaffected by inclusion of age, sex, and treatment (p=0.00064). VEGF (p=0.023) 
and CYFRA 21.1 (p=0.012) were also associated with survival after adjustment for 
covariates, whereas bFGF and SMRP were not (p=0.15, 0.26, respectively; table 
3.4). Unpenalised and penalised multivariable Cox regressions indicated that 
the five biomarkers were not predictive for thalidomide (unpenalised: p>0.10), 
and only interleukin 6 and CYFRA 21.1 were prognostic for survival, irrespective 







Toxicity No. % No. % No. %
Constipation 2 2 2 1
Fatigue 4 4 1 1 5 2
Neurosensory 2 2 2 1
Cardiac event 2 2 3 3 5 2
Thrombo embolic event 3 3 3 1
Anemia 2 2 2 2 4 2
Thrombocytopenia 7 6 11 10 18 8
Leucopenia 2 2 3 3 5 2
Neutropenia 14 12 10 8 24 10
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of treatment with thalidomide. The sensitivity analysis indicated that exclusion 
of the three (4%) patients missing an occasional biomarker measurement did 
not qualitatively change these results. The log-transformed (single predictor) 
prognostic value of interleukin 6 and CYFRA scores for overall survival were HR 
1.6 (95% CI 1.1–2.5) and 1.4 (1.1–1.7), respectively (figure 3.4). Patients with both 
reduced baseline interleukin 6 and CYFRA 21.1 values had improved prognosis, 
with a median overall survival of 17.1 months (95% CI 13.4–24.5) as opposed to 7.6 
months (6.7–12.2) for patients with both interleukin 6 and CYFRA 21.1 raised, and 
12.2 months (9.4–18.8) for patients with either interleukin 6 or CYFRA 21.1 raised 
(figure 3.5).







 Variable No. %   No. %   No. %
Treatment                
Supportive care 39 53   71 48   110 50
Thalidomide 34 47   77 52   111 50
Age, years
Median 64 64 64
Range (49–78) (41–82) (41–82)
Sex                
Female 7 10   27 18   34 15
Male 66 90   121 82   187 85
ECOG PS
0–1 73 100 143 97 216 98
2 0 0 5 3 5 2
TNM stage                
1–2 35 48   47 32   82 37
3–4 38 52   90 61   128 58
Unknown 0 0   11 7   11 5
Pathology
Epithelial 61 84 129 87 190 86
Other 12 16 19 13 31 14
Prior treatment                
Pemetrexed 2 3   5 3   7 3
Pemetrexed + Platinum 71 97   143 97   214 97
Response to first-line Pemetrexed therapy
CR 2 3 4 3 6 3
PR 20 27 53 36 73 33
SD 51 70   91 61   142 64
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Figure 3.4: Kaplan-Meier curves for overall survival, by interleukin 6 (A) and CYFRA 21.1 (B) divided 
at the upper limit of normal for healthy patients.
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Figure 4: Kaplan-Meier curves for overall survival, by interleukin 6 (A) and CYFRA 21.1 (B) divided at the upper limit of normal for hea
Interleukin 6 ULN=5·84 ng/L. CYFRA 21.1 ULN=1·9 μg/L. CYFRA 21.1=serum cytokeratin fragment 21.1. HR=hazard ratio.
Table 4: Model outcomes for univariable Cox proportional hazards models of overall survival
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patients in the active supportive care group. Grade 2 
constipation was reported for ten (9%) patients on 
thalidomide and two (2%) on active supportive care. 
Grade 2 thromboembolism was not reported for any 
patient. In the thalidomide group, 18 (16%) patients went 
off  study because of adverse events, primarily neuropathy 
and fatigue.
Serum samples for VEGF, bFGF, interleukin 6, CYFRA 
21.1, and SMRP analyses were collected pro spectively in 
73 patients. There was good agreement between the 
demographic profi les with and without biomarker 
samples. The main diff erence between the populations 
occurred in TNM stage, with a smaller proportion of late-
stage tumours in the marker cohort (table 3). Within the 
marker subgroup, demographic characteristics were well 
balanced between thalidomide-treated patients and those 
not treated. There was moderate correlation between the 
markers VEGF, inter leukin 6, and bFGF (Spearman 
correlations,   =0·30–0·45), with CYFRA 21.1 and SMRP 
more strongly correlated (  =0·60). No other pairwise cor-
relations were signifi cant.
Martingale residuals indicated that logarithmic trans-
formations of the biomarkers resulted in linear asso-
ciations with the log-hazard. After transformation, 
interleukin 6 was very strongly associated with survival 
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Figure 4: Kaplan-Meier curves for overall survival, by interleukin 6 (A) and CYFRA 21.1 (B) divided at the upper limit of normal for hea










VEGF 1·1 (0·6–2·1) 2·2 (1·1–4·2) 0·84 1·5 (1·1–2·2) 5·46 0·019 0·607
Interleukin 6 1·5 (0·8–2·9) 1·9 (1·0–3·7) 1·17 1·8 (1·3–2·5) 12·79 0·00096 0·615
bFGF 1·5 (0·8–2·9) 1·6 (0·9–2·8) 0·87 1·4 (0·9–2·2) 2·29 0·12 0·564
SMRP 0·8 (0·4–1·6) 1·3 (0·7–2·4) 1·24 1·1 (0·8–1·6) 0·37 0·54 0·546
CYFRA 21.1 1·2 (0·7–2·4) 2·1 (1·1–4·1) 1·06 1·4 (1·1–1·8) 5·59 0·011 0·611
Two models per marker, one with the marker divided into tertiles, and one with the marker as a continuous 
log-transformed predictor. The hazard ratios (HRs) of the discretised marker model are for the second and third tertiles 
relative to the fi rst, and in the log-transformed biomarker models the hazard ratios are for a change of one IQR. 
C-index=Harrell’s concordance index. bFGF=basic fi broblast growth factor. SMRP=soluble mesothelin-related peptides. 
CYFRA 21.1=serum cytokeratin fragment 1.1.
Table 4: Model outcomes for univariable Cox proportional hazards models of overall survival
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Figure 3.5: Kaplan-Meier curves for the population divided into three cohorts using the tertiles of 
the Cox regression linear predictor.
Patients with low baseline IL6 and Cyfra 21.1 have better prognosis. HR=hazard ratio. CYFRA 21.1=serum 
cytokeratin fragment 21.1.
Table 3.4: Model outcomes for univariable Cox proportional hazards models of overall survival. 
Two models per marker, one with the marker divided into tertiles, and one with the marker as a 
continuous log-transformed predictor. The hazard ratios of the discretized marker model are for the 
2nd and 3rd tertiles relative to the first, and in the log-transformed biomarker models the hazard ratios 
are for a change of one interquartile range.
Tertiles Log-transformed
HR (95% CI) IQR HR (95% CI) LL Chi-sq p-value C-index
VEGF 1.1 (0.6–2.1)
2.2 (1.1–4.2) 0.84 1.5 (1.1–2.2) 5.46 0.019 0.607
IL6 1.5 (0.8–2.9)
1.9 (1.0–3.7) 1.17 1.8 (1.3–2.5) 12.79 0.00096 0.615
bFGF 1.5 (0.8–2.9)
1.6 (0.9–2.8) 0.87 1.4 (0.9–2.2) 2.29 0.12 0.564
SMRP 0.8 (0.4–1.6)
1.3 (0.7–2.4) 1.24 1.1 (0.8–1.6) 0.37 0.54 0.546
Cyfra 21.1 1.2 (0.7–2.4)
2.1 (1.1–4.1) 1.06 1.4 (1.1–1.8) 5.59 0.011 0.611
IQR=Interquartile range; HR=Hazard ratio; CI=confidence interval; LL=Log-likelihood; Chi-sq=chi-square 
statistic; C-index= Harrell’s concordance index. 7
 ve biomark-
 rst-line treatment 
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chemotherapy and randomisation, and post-study 
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Figure 5: Kaplan-Meier curves for overall survival of the population divided into three cohorts using the 
tertiles of the Cox regression linear predictor




To our knowledge this is the first randomised study of switch maintenance therapy 
in patients with mesothelioma who did not progress on first-line treatment with 
a pemetrexed-containing therapy (panel). We show that thalidomide did not have 
any positive effect in the maintenance setting in this selected study population. 
The observed time to progression between the two groups was nearly identical. 
We explored potential reasons for these findings. 
One consideration is that the dose of thalidomide might have been too low. In this 
study the patients received a median weekly dose of 1,200 mg. Although grade 3 
or higher neurosensory toxicity occurred only in 2% of patients using thalidomide, 
disabling grade 2 neurotoxicity occurred in 18% of patients as opposed to none 
in the active supportive care group. Previous treatment with cisplatin might have 
aggravated neurotoxicity in the thalidomide-treated group. In other diseases, such 
as multiple myeloma, a dose of thalidomide of 200 mg has a biological effect and 
with an acceptable toxicity profile. Furthermore, no evidence exists to support 
a dose–response relationship for thalidomide in treatment of diseases such as 
multiple myeloma or solid tumours.10,19 Other studies in breast cancer and small-
cell lung cancer tested higher doses of thalidomide and reported increased toxicity 
and poor compliance.10,20 Use of higher doses of thalidomide in this trial is likely to 
have resulted in increased toxicity.
Second, we considered whether a possible beneficial effect of thalidomide could 
have been outweighed by an imbalance in the first-line treatment. Factors such as 
chemotherapy dose intensity, interval between chemotherapy and randomisation, 
and post-study treatment were evaluated. In this study the stratification process 
led to an even balance for the different chemotherapy regimens between the 
two randomised groups. The number of courses given in first-line treatment were 
equal and the interval between end of first-line therapy and randomisation was 
identical: 1.2 months in both groups. Although follow-up for post study treatment 
was not complete, a subset analysis of 160 patients did not show any difference.
One of the limitations of the study was the definition of active supportive care. 
Active supportive care was properly defined by national guidelines and was 
given to patients irrespective of treatment group. Since information about active 
supportive care received by patients was not a primary or secondary outcome, 
we cannot report on the use of this approach in detail. According to the treating 
physicians there was no reason to believe that there was a misbalance in care. If 
we can conclude from this study that there was no benefit of thalidomide, then 
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the absence of a significant difference in the final outcome of this study, time 
to progression and overall survival, strengthens the opinion that equal active 
supportive care was received by both groups. Furthermore, we realise that by 
undertaking this study in two affluent countries, using our inclusion and exclusion 
criteria, a selection of the fittest patients has taken place. This study does not 
allow us to comment on the effect of thalidomide in less fit patients, nor a possible 
response to thalidomide in patients who progressed after first-line chemotherapy. 
We were reluctant to include these patients in our study, since in the preceding 
phase 2 study15 no partial responses were seen in this particular group. In our 
opinion inclusion of patients with progressive disease would not have been ethical, 
since they had had a 50% chance of treatment with active supportive care only and 
probably had no chance of response with thalidomide. Furthermore the idea of the 
study was to consolidate the effect of chemotherapy and switch to maintenance 
therapy in patients whose tumours had not progressed.
The mechanism of action of thalidomide is not fully understood.21 Apparently the 
drug does not work in mesothelioma and has not been shown to be effective in 
other solid tumours. A large randomised phase 3 maintenance study of thalidomide 
in patients with non-small-cell lung cancer did not improve survival.11 Thalidomide 
also failed as maintenance therapy in small-cell lung cancer and as single agent 
treatment in breast cancer.10,12 The lack of benefit for thalidomide is consistent 
with other studies using antiangiogenic treatments in malignant mesothelioma. 
In a randomised phase 2 study22 investigating the effect of bevacizumab, a VEGF 
monoclonal antibody, in patients receiving cisplatin and gemcitabine, bevacizumab 
did not improve outcome. Although in this study an exploratory subset analysis 
showed improved survival for the bevacizumab chemotherapy regimen in patients 
with low circulating VEGF. Other phase 2 studies tested drugs with antiangiogenic 
properties such as sorafenib,23 sunitinib,24 vatalanib,25 and cediranib,26 for 
malignant mesothelioma, all of which reported low response rates and did not 
show any antitumour activity. One phase 2 study27 showed modest activity of 
cediranib after previous platinum-based therapy. Four (9%) patients in this single 
group study showed partial responses, which did not meet the prespecified 20% 
response rate of interest. However, there was marked shrinkage of bulky tumours 
in two of the four patient responders,27 which gave reason to proceed with a larger 
randomised phase 2 trial testing cediranib in combination with pemetrexed and 
cisplatin. A second phase 2 study28 of sunitinib as second-line therapy reported 
modest activity in progressing patients, but was unable to identify any serum 
biomarkers of response in angiogenesis pathways. In France, a large randomised 
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phase 3 study testing the addition of bevacizumab to pemetrexed and cisplatin is 
ongoing (NCT00651456).
In this study five biomarkers, VEGF, bFGF, interleukin 6, CYFRA 21.1, and SMRP, were 
tested for their prognostic and predictive performance. None were predictive for 
thalidomide efficacy. Interleukin 6 and CYFRA 21.1 were prognostic for survival. 
Patients with low interleukin 6 and with low CYFRA 21.1 concentrations had the 
best prognosis. Although interleukin 6 is not known for its prognostic performance 
in malignant mesothelioma, it is a prognostic factor in other diseases such as 
renal-cell carcinoma.29 High concentrations of interleukin 6 have been detected 
in the pleural fluid of patients with malignant mesothelioma17 and could be the 
cause of high serum interleukin 6 concentrations that induce clinical inflammatory 
reactions. These findings might be interesting to pursue in further studies. 
Although SMRP seems to be a promising tumour marker in mesothelioma,30 we 
did not find an association with survival. A possible reason for the absence of 
prognostic value might be the time of measurement and the eligibility criteria of 
the patients. Samples were taken after first-line chemotherapy, and we did not 
include patients who had progression at that time. Since SMRP is suggested to be 
associated with disease status, the possible value of SMRP as a prognostic marker 
could be underestimated in our study. The major limitation of the biomarker 
study was the size of the cohort, and thereby the potential bias due to selection. 
Although the demographic characteristics of patients who were included in 
the biomarker study were similar to those who were not included, it cannot be 
ruled out that the apparent prognostic values of interleukin 6 and CYFRA 21.1 
are cohort-specific (i.e., type I errors). Furthermore, the small sample size greatly 
reduces the chance of finding small effects (type II errors), especially since the 
power of detecting predictive associations is low. Hence we regard these results 
as hypothesis-generating, needing validation in larger, more extensive series.
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A randomised phase 2 study adding axitinib to pemetrexed-cisplatin in patients 
with malignant pleural mesothelioma: a single center trial combining clinical and 
translational outcomes
Introduction: Mesothelioma often presents with a high vessel count and increased 
vascular growth factors levels. Interference with angiogenesis may therefore improve 
outcome. This study reports on clinical and translational parameters in patients 
treated with the small molecule tyrosine kinase inhibitor axitinib and chemotherapy.
Methods: Chemo-naïve patients with mesothelioma were eligible. Patients received 
pemetrexed (500 mg/m2 q3wk) and cisplatin (75 mg/m2 q3wk) and were randomised 
to receive daily axitinib (2x5 mg tablets d2–19) or observation. Before treatment and 
after 3 cycles of chemotherapy, a thoracoscopy was performed to evaluate vascular 
changes.
Results: 25 patients were randomised after a successful lead-in with 6 patients 
receiving axitinib. Median follow-up was 45 months. In all, but one patient, it was 
feasible to perform a second thoracoscopy. However, there was more grade 3,4 
neutropenia in the axitinib group leading to pneumonia. Rates of PR and SD were in 
the axitinib arm 36% and 43% compared to the chemotherapy alone arm 18% and 
73%. Median PFS and OS (5.8 and 22.1 months versus 8.3 and 18.5 months) were not 
different. Axitinib reduced vessel number and vessel immaturation. Yet, mRNA levels 
of a number of vascular growth factors, their receptors, serum VEGF and activation 
of tissue VEGFR2 were increased. Gene expression of PDGFRB, FLT1 and FLT4 even 
correlated with outcome.
Conclusions: Axitinib was well tolerated in combination with cisplatin and pemetrexed. 
Despite the lack of a clinical benefit, axitinib reduced angiogenesis. Whether changes 
in differentially expressed growth factors in tissue and serum may serve as biomarker, 
needs further investigation.




Malignant mesothelioma is one of the fatal diseases caused by exposure to 
asbestos fibers, and long-term survivors are rare. Mesothelioma is refractory to 
different treatment modalities and currently, chemotherapy is regarded to be the 
best available treatment option. Two large phase 3 studies have been published 
found that the combination of cisplatin with an antifolate drug (pemetrexed or 
raltitrexed) significantly improves both response rate and median overall survival 
compared with cisplatin alone, with a survival benefit of 2.8 months in the first-line 
setting.1, 2 Unfortunately, in most patients the disease progresses within the first 6 
months and only 20% are alive at 2 years’ follow-up, indicating that improvements 
are urgently needed.
An important target in cancer therapy is the tumour vasculature. Tumour growth 
is strongly dependent on angiogenesis and new feeding vessels are needed when 
tumour growth progresses.3, 4 Mesothelioma cells often overexpress vascular 
endothelial growth factor receptor 2 (VEGFR2).5 Circulating concentrations of 
vascular endothelial growth factor (VEGF) in patients with malignant pleural 
mesothelioma are found to be even higher than in patients with other solid tumours 
or in healthy individuals.6 Both VEGF concentrations in the serum and microvessel 
density have been identified as negative prognostic factors in malignant pleural 
mesothelioma.7, 8
Axitinib is a potent oral inhibitor of mainly the tyrosine kinase receptors for VEGF, 
namely vascular endothelial growth factor 1 (VEGFR-1), VEGFR2 and VEGFR3. 
Axitinib has shown antitumour effects in solid tumours9, 10 and has a mild toxicity 
profile, mainly consisting of hypertension, diarrhea and fatigue. We performed a 
phase 2 study, in which patients with mesothelioma were treated with pemetrexed 
and cisplatin and randomised to receive axitinib or no additional treatment.
One of the major limitations in the response evaluation of mesothelioma patients 
is the lack of sensitivity of the standard evaluation procedures for measuring 
response. The Response Evaluation Criteria In Solid Tumors (RECIST) criteria, 
including modified RECIST, often fail to determine the exact effect of a new drug. 
Therefore, an approach matching both non-invasive analysis and biological effects 
is of great importance. For this reason, in the study reported here, response 
evaluation was achieved with a computed tomography (CT) scan and a second 
thoracoscopy, which was performed after three courses of systemic therapy, to 
study intratumour changes. On the basis of axitinib’s mechanism of action, we 
focused on the changes in vascularisation in paired tumour biopsy samples. 
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The current study had both clinical and translational objectives. For the clinical 
outcome, we aimed at examining the additive effect of axitinib in relation to 
toxicity, response rate (RR), progression-free survival (PFS) and overall survival 
(OS). For RR, PFS and OS, only the randomised patients were studied. We also 
investigated the feasibility of performing a second thoracoscopy after three cycles 
of therapy. In the translational part of the study, vascular effects were assessed by 
measuring serum and tissue levels of vascular growth factors and by determining 
number and maturity of microvessels with immunohistochemical analysis.
Materials and methods
Study design
In this open-label, single-center study, treatment naïve patients with suspected 
or proven malignant mesothelioma were treated with pemetrexed and cisplatin 
and randomly assigned to receive either a combination of axitinib, pemetrexed 
and cisplatin or pemetrexed and cisplatin alone. Before the start of treatment, a 
thoracoscopy was performed to confirm the diagnosis of mesothelioma. After three 
cycles of therapy, a second thoracoscopy was performed to obtain adequate biopsy 
samples (partial pleurectomy). During both procedures, tumour biopsy material 
was obtained for research purposes. After the partial pleurectomy, patients could 
continue with an additional three cycles of chemotherapy, but without axitinib. To 
test the safety and tolerability of adding axitinib to the standard treatment and 
to prove the feasibility of the protocol, a lead-in cohort received chemotherapy 
plus axitinib. The study was approved by the local institutional review board. All 
patients provided written informed consent. The study was registered under 
NCT01211275. 
Patients
Eligible patients had suspected or proven malignant pleural mesothelioma and 
were considered candidates for standard chemotherapy. They were medically 
suitable for limited surgical intervention and not considered candidates for 
trimodality treatment. An expert pathology panel confirmed the diagnosis in all 
cases. The presence of a measurable lesion on CT was not a prerequisite. Other 
eligibility criteria were a World Health Organization performance status of 2 or 
less, an adequate bone marrow reserve and sufficient hepatic and renal function. 
Key exclusion criteria were uncontrolled hypertension, severe cardiac dysfunction, 
uncorrectable bleeding tendency and previous successful pleurodesis.
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Treatment and procedures 
Patients were treated with pemetrexed 500 mg/m2, and cisplatin 75 mg/m2, 
repeated every three weeks, and they were randomised 1:1 to receive either 
axitinib, 5-mg tablets twice a day from day 2 until day 19 or chemotherapy only. 
The six patients in the lead-in cohort all received pemetrexed cisplatin and axitinib. 
If hypertension (defined as blood pressure >140/90 mmHg on 2 consecutive 
occasions >24 hours apart) occurred during axitinib treatment, the first choice of 
treatment was a long acting calcium channel blocker. Dose reductions of axitinib 
were described in the protocol. Before the start of treatment, a CT scan of the 
chest was performed. In addition, a thoracoscopy was performed to confirm the 
diagnosis and to obtain biopsy samples for research purposes. Treatment was 
started within three weeks of these interventions. After three cycles of therapy, 
a second CT scan of the chest was performed, allowing a pre-debulking response 
evaluation and a second thoracoscopy was carried out for a palliative pleurectomy 
and to obtain biopsy samples. Treatment with axitinib was discontinued five 
days before this surgery. During both procedures, photographs were taken at 
pre-specified locations (apex, diaphragm, lateral parietal pleura) to localize the 
areas where the initial biopsy samples were obtained. Patients could receive an 
additional three cycles of chemotherapy, but treatment with axitinib was not 
continued. After completing treatment, patients were followed every 6 weeks for 
the first 6 months, thereafter every two months. A safety analysis was performed 
at baseline and every 10 days thereafter for the duration of treatment and after 
treatment per the the follow-up schedule. Toxicities were assessed according to the 
Common Terminology Criteria for Adverse Events version 3.0. Response rate after 
three cycles of therapy was assessed according to the modified RECIST version 1.1 
guidelines. Before the start of treatment and on day one of each treatment cycle, 
serum samples were taken from each patient. Samples were stored at -30°C untill 
analysis. Biopsy samples were either snap-frozen in liquid nitrogen for analysis of 
mRNA expression and protein levels or formalin fixed and processed for paraffin 
embedding and subsequent immunohistochemical analysis.
Quantitative polymerase chain reaction (qPCR)
For the quantative polymerase chain reaction (qPCR), biopsy samples were cut 
into 30x30-µm sections and homogenised in RNA-Bee (Bio-Connect, Huisen, the 
Netherlands). Samples were centrifuged and the supernatant was precipitated 
overnight with isopropanol at -20°C. Pellets were washed with 70% ethanol 
and dissolved in water. An RNeasy Kit (Qiagen, Hilden, Germany) was used for 
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purification of the RNA and DNAse treatment according to the manufacturer’s 
protocol. cDNA synthesis was performed with Superscript II RT (Life Technologies, 
life Technologies, Grand Island, NY) with random primers. qPCR was performed 
with SYBR green (Life Technologies) on the Applied Biosystems 7500 Fast Real 
Time PCR system (Thermo Fisher Scientific, Waltham, MA). Changes in gene 
expression were analysed with the comparative CT method. The glyceraldehyde 
3-phosphate dehydrogenase gene (GAPDH) and beta-2-microglobulin gene (B2M) 
were used as reference genes. After correction for the geometric mean of the 
reference genes, gene expression in each sample was related to the median gene 
expression of all samples before treatment. Results are displayed as fold change 
of gene expression in each biopsy sample compared with the median value of the 
patients before treatment, which was set to 1. For the correlation studies, mRNA 
expression after treatment was divided by mRNA expression before treatment to 
obtain the fold change in mRNA levels during therapy.
Western blotting 
Biopsy samples were cut into sections and homogenised in lysis buffer (50 mM Tris-
HCl [pH8], 150 mM NaCl, and 1% NP40, plus phosphatase and protease inhibitors) 
using a Polytron mixer (Kinematica, Luzern, Switzerland). After incubation for 10 
minutes on ice, samples were centrifuged and the protein concentration in the 
supernatant was determined with the Bio-Rad Protein assay (Bio-Rad, Hercules CA). 
After boiling in 5x sodium dodecyl sulfate sample buffer, lysates were subjected to 
gel electrophoresis and subsequent Western blotting. Membranes were probed with 
antibodies against VEGFR2 (Cell Signaling Technology, Danvers, MA), pVEGFR Tyr951 
(Santa Cruz Biotechnology, Dallas, TX), VEGF (Abcam, Cambridge, United Kingdom) 
and beta-actin (Sigma-Aldrich). Western Blots were performed twice and the average 
values of both experiments were used for analysis. Protein levels were quantified 
on inverted pictures using Adobe Photoshop (Adobe) tools. The measured intensity 
of each band was multiplied with the band size (in pixels) to obtain the “absolute 
intensity”. “Relative intensity” was calculated by dividing the respective absolute 
intensities of the VEGF, VEGFR2 and pVEGFR2 bands by the absolute intensity of 
beta-actin. pVEGFR2 absolute intensities were also divided by VEGFR2 absolute 
intensities to obtain VEGFR2 activation corrected for total VEGFR2 levels. 
VEGF and soluble VEGFR2 Elisa
VEGF and soluble VEGFR2 concentrations in patient serum samples were 
determined with the Quantikine human VEGF and Soluble VEGFR2 immunoassays 
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(R&D Systems, Minneapolis, MN) according to instructions of the manufacturer. 
As VEGF is mainly secreted by platelets, VEGF levels are displayed as VEGF 
concentration per 109 platelets. 
Immunohistochemical analysis
Tissues were fixed in paraformaldehyde and paraffin embedded. Next, 5-μm 
sections were deparaffinized and rehydrated in graded ethanol series. Heat-
induced epitope retrieval was performed in sodium citrate buffer using a 
pressure cooker. Non-specific binding was blocked with 5% bovine serum albumin. 
Sections were incubated with an antibody against the endothelial marker CD31 
(1:100, clone EP3095 [Millipore]) and with a horseradish peroxidase-conjugated 
secondary antibody. Incubation with diaminobenzidine was used to visualise blood 
vessels. Thereafter, sections were incubated with anti-smooth muscle actin (1:100, 
clone 1A4, [DAKO, Glostrup, Denmark]) and an alkaline phosphatase-conjugated 
secondary antibody, which was used to visualise the pericyte coverage of the 
blood vessels. Vasculature covered with pericytes was considered to represent 
the mature and pre-existing vasculature, whereas blood vessels with a low level 
of pericyte coverage were considered to be the immature and newly formed 
vasculature. Sections were mounted in aqueous mounting solution. Microvessel 
density was assessed by counting the number of blood vessels in 10 randomly 
chosen high-power microscopic fields. Immature blood vessels are enumerated by 
counting the number of blood vessels in 10 microscopic fields without associated 
pericytes.
Statistical analysis
The primary endpoint was defined as the feasibility of a second thoracoscopy 
after combination chemotherapy. The secondary endpoint was the toxicity of 
axitinib when added to the standard of care. For the primary research question 
of evaluating the additional value of axitinib on tumour vessels and feasibility of 
the second thoracoscopic intervention, it was estimated that a randomised setting 
with approximately 10 patients in each arm would be sufficient. Differences in 
toxicity were tested by means of a Fisher’s exact test. PFS was defined as time 
from randomisation to progression or death, whichever was observed first. 
Overall survival was defined as time from randomisation to death from any cause. 
Survival curves were produced using the Kaplan-Meier technique, and the groups 
were compared with a log-rank test. Analysis was performed using R version 3.1 
(R Foundation, Vienna, Austria). Randomisation was based on a block design with 
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block of size 4.11 Because of the small sample size, no stratification factors were 
used. GraphPad Prism (GraphPad Software, LaJolla, CA) was used for statistical 
analyses of mRNA and protein analysis. Matched samples (before and after 
treatment) were compared by using a Wilcoxon matched-pairs signed rank test. 
To measure the degree of association between changes in mRNA expression and 
clinical outcome, a Spearman correlation was used. P-values less than 0.05 were 




From July 2009 until October 2012, 32 patients were included in this study. The 
first six consecutive patients received chemotherapy and axitinib, being part of 
the lead-in cohort. The remaining 26 patients were randomised. One patient in the 
chemotherapy-only group withdrew consent before start of treatment, and was 
excluded from analysis. In total, 20 patients received chemotherapy and axitinib 
and 11 patients chemotherapy only. The baseline characteristics of the patients 
are shown in table 4.1. 










Sex      
Male 6 9 10 25 (81%)
Female 0 5 1 6 (19%)
Age (years)
Median 57 63 59 61
(Range) (56–61) (51–75) (35–74)  (35–75)
Histology      
Epithelial 4 12 10 27 (87%)
Mixed 1 1 1 2 (6%)
Mesenchymal 1 1 0 2 (6%)
Performance status
WHO 0–1 5 13 11 29 (94%)
WHO 2 1 1 0 2 (6%)
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Drug exposure, dose modification
Within the chemotherapy-only group, all patients received the planned three 
cycles of cisplatin and pemetrexed. In the chemotherapy with axitinib group two 
patients in the randomised cohort were changed to carboplatin in the third cycle, 
owing to decreased renal function, as prespecified in the protocol. Progressive 
disease developed in one patient in the lead-in phase after two cycles, and the 
patient went off study. Because of hypertension, one patient in the randomised 
group had a dose reduction of two levels of axitinib, according to the protocol.
Toxicity 
There were no grade 5 toxicities reported. Table 4.2 shows the rate of grade 2 to 4 
adverse events in all 31 treated patients. In particular, as expected, hypertension 
grade 2 was significant more often observed in the axitinib group than in the group 
without axitinib (p=0.01). All patients treated with axitinib experienced some 
grade 3 or 4 toxicity. This was mainly due to the presence of neutropenia, which 
occurred in nine patients (45%) of the axitinib group versus only one patient (9%) 














Haemoglobin 2 (10%) 2 (18%) 1 (5%) 0 0 0
Leucocytes 8 (40%) 3 (27%) 1 (5%) 0 1 (5%) 0
Neutrophils 10 (50%) 4 (36%) 8 (40%) 1 (9%) 1 (5%) 0
Thrombocytes 2 (10%) 0 0 0 1 (5%) 0
Other
Hypertension 9 (45%) 0 1 (5%) 0 0 0
Nausea 3 (15%) 3 (27%) 1 (5%) 0 0 0
Vomiting 1 (5%) 0 1 (5%) 0 0 0
Obstipation 0 1 (9%) 2 (10%) 0 0 0
Fatigue 6 (30%) 3 (27%) 0 0 0 0
Headache 1 (5%) 0 0 0 0 0
Stomatitis 0 0 0 0 0 0
Neuropathy 0 0 0 0 0 0
CVA 0 0 1 (5%) 0 0 0
Lung embolism 1 (5%) 0 0 0 0 0
Prostatitis 0 0 1 (5%) 0 0 0
Pneumonia 0 0 1 (5%) 0 0 0
Hiccups 0 0 1 (5%) 0 0 0
Obstruction airway 1 (5%) 0 0 0 0 0
Mobitz type II 0 0 1 (5%) 0 0 0
Total (any AE) 44 16 20 1 3    0
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in the chemotherapy-only group. Neutropenia was complicated by pneumonia 
once in the axitinib group (5%). There were two (10%) thrombotic events in the 
axitinib arm: in one patient developed grade 2 pulmonary embolism developed 
during axitinib treatment and in one patient a grade 3 cerobrovascular accident 
(CVA) developed, 2 days after the second thoracoscopy. Both events were possibly 
related to the axitinib treatment.
Response rate, PFS, OS 
Supplementary table S4.2 summarises the best overall response on the CT scan 
after 3 cycles of therapy of the 25 randomised patients. There was no difference 
in the number of responders between the groups (p=0.85). Complete responses 
were not observed. The rates of partial response (PR) and stable disease (SD) 
in the two arms were 36% and 43% in the axitinib arm and 18% and 73% in the 
chemotherapy-only arm, respectively. With a median follow up time of 45 months, 
median PFS was 5.8 months (95% CI 4.6–24) in the axitinib group and 8.3 months 
(95% CI 6–NA) in the chemotherapy-only group (p=0.86) (figure 4.1A). Median OS 
was 18.9 months (95% CI 11.2–NA) in the axitinib group and 18.5 months (95% CI 
13.7–NA) in the chemotherapy-only group (p=0.78) (figure 4.1B).
Feasibility of performing a second thoracoscopy
A second thoracoscopy and partial pleurectomy were performed in all 11 patients 
treated with chemotherapy only. In the axitinib group, 16 out of the 20 patients 
received a second thoracoscopy including a partial pleurectomy. A pulmonary 
embolus developed in one of the randomised patients, and an arrhythmia, 
Mobitz type II, that required a pacemaker developed in another patient. In the 
lead-in group, one patient refused a second thoracoscopy, but consented to 
CT-guided biopsy samples; the disease of one patient progressed beforehand. 
The second thoracoscopy and partial pleurectomy were in general well tolerated. 
The median hospital stay was six days and similar in both groups (4–11 days). 
Postoperative complications were more often seen in the axitinib group, but this 
was not significant (p=0.32). Fever of unknown origin (the only complications in 
the lead-in cohort) developed in two patients. One patient had a prolonged air 
leak lasting 9 days; one had persistent pain that resolved with medication; and 
a CVA that was possibly related to the study drug developed in one patient on 
the second postoperative day, but the patient recovered completely. A complete 
pneumothorax developed in one patient on the 26th postoperative day, but it was 
treated successfully with talc pleurodesis. No prolonged bleeding tendencies or 




















20 17 9 6 4 4 3 3 1
11 10 8 5 3 2 2 1
Axitinib
no Axitinib
Median PFS (95% CI)
Axitinib 5.8 ( 4.6 − 11.1 )
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no Axitinib
Median OS (95% CI)
Axitinib 18.9 ( 11.2 − NA )
no Axitinib 18.5 ( 13.7 − NA )
log−rank p−value 0.77
Figure 4.1: (A) Kaplan-Meier curve for progression-free survival of all 25 randomised patients. 





impaired wound healing were observed. In the chemotherapy-only group, one 
patient had persistent pleural fluid production, that resolved after a second talc 
pleurodesis.
Supplementary table S4.1 presents an overview of treatments received by all 
patients.
Supplementary figure S4.1 shows the thoracoscopy of a patient treated with 
pemetrexed cisplatin and axitinib before and after therapy. There is a clear 
reduction of tumour load after therapy.
Microvessel density and immature blood vessels
There was a significant increase in microvessel density in the tumour biopsy 
samples after treatment with pemetrexed and cisplatin compared with in the 
biopsy samples before treatment (p<0.0001) (figure 4.2A). In addition, the number 
of immature blood vessels increased after chemotherapy in this group (p=0.0003) 
(figure 4.2B). In contrast, in the axitinib group, microvessel density and the number 
of mature blood vessels remained the same after treatment.
mRNA expression of angiogenic growth factors and their receptors 
In tumour biopsy samples, levels of mRNA expression of fibroblast growth factor 
receptor 1 (FGFR1), platelet-derived growth factor receptor beta (PDGFRB), fms-
related tyrosine kinase 1 (FLT1/VEGFR1), kinase insert domain receptor (KDR/
VEGFR2) and fms-related tyrosine kinase 4 (FLT4/VEGFR3) and their respective 
ligands fibroblast growth factor 2 (FGF2), platelet-derived growth factor beta 
(PDGFB), placental growth factor (PGF/PlGF), vascular endothelial growth factor A 
(VEGFA) and vascular endothelial growth factor C (VEGFC) were determined before 
and after systemic therapy. Expression of the angiogenic growth factors FGF2, 
PDGFB and to a lesser extent of PGF, and their corresponding receptors FGFR1, 
PDGFRB and FLT1 were significantly up-regulated after treatment with axitinib. 
VEGFA and VEGFC as well as their receptors KDR and FLT4 were not differentially 
regulated after axitinib treatment; although we observed a slight decrease in 
VEGFA expression in the chemotherapy-only group (figure 4.3A). mRNA levels of 
PDGFRB, FLT1 and FLT4 correlated with clinical response in both patient groups 
irrespective of axitinib treatment: higher expression levels of all three receptors 
were significantly associated with worse outcome (figure 4.3B). 
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Figure 4.2: (A) Microvessel density (MVD) before (yellow) and after (green) treatment. In the 
chemotherapy-only group (no axitinib) there is an increase in MVD (p<0.0001). MVD was measured 
in number per mm3. (B) Blood vessel maturity before (yellow) and after (green) treatment. In the 
chemotherapy-only group (no axitinib) there is an increase in immature blood vessels (p=0.0003). 
Immature blood vessels are depicted as number of blood vessels without associated smooth muscle 










Figure 4.3: (A) Increased mRNA expression of fibroblast growth factor receptor 1, platelet-derived 
growth factor receptor beta, and fms-related tyrosine kinase 1 and their ligands fibroblast growth 
factor 2, platelet-derived growth factor beta, and placental growth factor after treatment with axitinib. 
(B) Changes in mRNA levels (after versus before treatment) of platelet-derived growth factor receptor 
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Levels of VEGF and VEGFR2 in serum and tissue
In the serum, soluble VEGFR2 levels decreased during axitinib treatment while 
VEGF levels increased (supplementary figure S4.2). In contrast, tissue protein levels 
of VEGF and VEGFR2 were not affected by axitinib treatment (supplementary 
figure S4.3). Activation of VEGFR2 was significantly increased in the tumour biopsy 
samples after axitinib treatment. However, this effect disappeared when pVEGFR2 
levels were corrected for VEGFR expression. In the chemotherapy-only group, 
VEGF levels decreased after treatment. Interpatient variation in VEGF and VEGFR2 
levels or VEGFR2 activation were not correlated with clinical response.
Discussion
To our knowledge this is the first randomised phase 2 study of treatment of 
patients with mesothelioma with the combination of pemetrexed, cisplatin and 
the small molecule tyrosine kinase inhibitor axitinib. This study did not find a 
statistical difference in median PFS and OS between the randomised groups. This 
outcome did not change when all the 31 treated patients (including those in the 
lead-in group) were compared. 
An aim of our study was to correlate possible clinical effects of axitinib to 
alterations in angiogenic growth factor levels, which may be used as biomarkers. 
Therefore, changes in intratumour vascularisation were explored. Axitinib 
treatment efficiently prevented tumour neoangiogenesis and improved vessel 
maturation compared with tumour biopsy samples from patients treated with 
chemotherapy alone. However, analysis of mRNA expression found that levels of 
most of the angiogenic ligands and their receptors were increased after treatment 
with axitinib. This might reflect a rebound effect caused by stopping axitinib 
treatment for safety reasons, 5 days before the second thoracoscopy. Increased 
VEGF levels in serum and a slight increase in activity of tissue VEGFR2 further 
support this hypothesis. Yet, it is also possible that increased mRNA expression of 
angiogenic growth factors and their receptors were a compensatory reaction to 
the inhibition of the VEGF signaling axis by axitinib. 
The importance of not only controlling VEGF/VEGFR2 signaling, but also balancing 
other signaling pathways was underlined by the finding that increased mRNA 
expression of vascular (PDGFRB and FLT1/VEGFR1) and lymphatic (FLT4/VEGFR3) 
growth factor receptors was strongly correlated with worse prognosis; partial 
regression was only observed in patients with the lowest expression levels. 
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Because of the small study size, we were not able to assign clinical outcomes to 
treatment groups. 
In addition, we assessed serum levels of the extracellular domain of VEGFR2 (i.e., 
soluble VEGFR2), which can be released from endothelial cells through alternative 
splicing or proteolytic processing.12-14 Similar to our findings, decreased levels of 
soluble VEGFR2 in the blood – and an increase in VEGF levels – have been measured 
in patients with thoracic cancer who were treated with different VEGFR inhibitors.15 
Studies in tumour-free mice treated with sunitinib – a receptor tyrosine kinase 
inhibitor that blocks both PDGF and VEGF signaling – suggest that increased levels 
of VEGF and decreased levels of soluble VEGFR2 levels may be a systemic response 
to drug treatment.16 Future studies may investigate whether there is a correlation 
of soluble VEGFR2 with clinical outcome. 
Another important issue of this study was the feasibility of performing a second 
thoracoscopy after 3 cycles of (chemo)therapy. Such a procedure grants the 
opportunity to retrieve biopsy samples at different time points and to compare 
clinical effects of new drugs to translational outcomes in a relatively small study. 
In only one patient, a pleurectomy was not possible owing to severe adhesions. 
There were more postoperative complications seen in the axitinib group, but this 
difference was not significant. No tendency toward prolonged bleeding or wound 
healing impairment –side effects related to the use of angiogenesis inhibitors – 
were observed. 
The combination of chemotherapy with axitinib was well-tolerated. Neutropenia 
occurred more often in the experimental arm, as was also previously reported.17, 18 
It lead to pneumonia in only one patient in the lead-in cohort. Although reports 
about the combination of VEGF inhibitors and thromboembolic events are 
controversial,19, 20 the occurrence of thromboembolic events was more alarming. 
A (transient) CVA developed in one patient on the second postoperative day (on 
day 7 after axitinib was stopped) and lung emboli developed in one patient during 
treatment. It is conceivable that the development of the CVA was not caused 
by axitinib but by the use of cisplatin or the operation itself. The occurrence of 
lung emboli in patients with malignancies is a known complication. An association 
between hypertension during VEGF inhibition and positive clinical response has 
been noticed.21 In four of five patients in the axitinib group who had a partial 
response, hypertension developed during treatment. However, this was not seen 
in the two patients in the control group who had a partial response. The association 
was not seen with respect of the time-to-event outcomes. 
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We considered whether a possible beneficial effect of axitinib could have been 
outweighed by an imbalance in treatment given after the second thoracoscopy 
or further line treatment. Indeed, in the axitinib group fewer patients received 
one or more additional cycle of pemetrexed containing therapy after the second 
thoracoscopy (43% versus 73% in the chemotherapy-only group). Post study 
therapies were given equally (to 45% of patients in both groups). One of the 
limitations of the study was the measurement of PFS and OS in relation to the 
medication given whereas all patients underwent cytoreduction after 3 cycles of 
therapy. This may be a confounding factor towards progression and survival. On 
the other hand, patients in both groups received a pleurectomy and in such a small 
cohort PFS and OS should always be interpreted with care.
The effect of axitinib in studies of other solid tumours has been variable. In a phase 
3 trial comparing the efficacy and safety of axitinib versus sorafenib as second-
line treatment for metastatic renal cell carcinoma, patients who received axitinib 
had a longer PFS. These results established axitinib as a second-line treatment 
option in this patient group.9 A randomised phase 2 trial of gemcitabine with 
or without axitinib in advanced pancreatic cancer suggested increased overall 
survival in axitinib-treated patients, but a randomised phase 3 study of the drug 
failed to confirm this.22 Axitinib was also tested in a randomised phase 2 study in 
advanced nonsquamous non-small cell lung cancer. The drug was combined with 
pemetrexed/cisplatin and was generally well tolerated. The combination however 
did not improve PFS or OS compared with chemotherapy alone.23
The fact that no positive clinical signals of the addition of axitinib were observed 
in our study is consistent with other studies using antiangiogenic treatments 
in mesothelioma. A variety of antiangiogenic drugs have been tested as single 
agents in phase 2 studies. These include sunitinib,24, 25 vatalanib26 and sorafenib,27 
all of which have been reported as being associated with low response rates and 
not showing any anti-tumour activity. One single arm phase 2 study found modest 
activity of cediranib after previous platinum-based therapy.28 Although the study 
did not meet its prespecified response rate, there was a marked shrinkage of bulky 
tumours in two of the four responders. This was considered a reason to proceed 
with a randomised phase 2 trial, testing cediranib in combination with pemetrexed 
and cisplatin. In a randomised phase 2 study investigating the effect of bevacizumab 
in patients receiving cisplatin and gemcitabine, bevacizumab did not improve 
outcome.29 The large randomised phase 3 study testing thalidomide versus active 
supportive care in a maintenance setting, after first-line chemotherapy found no 
benefit in terms of PFS or OS for the experimental arm.30 The first results of a large 
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randomised phase 3 study testing the addition of bevacizumab to pemetrexed and 
cisplatin performed in France indicated a significant improvement in OS for the 
experimental arm (NCT00651456).31 However the full paper has to be awaited.
One of the strong points of our study is that despite the small sample size, patients 
were randomly allocated to standard and experimental therapy at the same time 
as translational research was being used in the search for valuable biomarkers that 
would support the use of a new drug. Especially with a low-incidence disease and 
huge numbers of candidate drugs and potential biomarkers, small studies need 
to efficiently provide valuable information. Randomising even small numbers of 
subjects and including standard treatment is the most efficient mechanism to 
quickly gather relative unbiased data for screening purposes. 
In conclusion, we showed that it is feasible to perform a second thoracoscopy in 
patients with malignant pleural mesothelioma who are treated with pemetrexed 
cisplatin and axitinib. The combination was well tolerated, and no signs of clinical 
activity were observed. Strong correlations of (lymph)angiogenic factors with 
clinical outcome suggest that vascular alterations and/or neovessel formation play 
an important role in mesothelioma; however, this study also demonstrates that 
only reducing microvessel density and increasing the maturity of blood vessels is 
not sufficient to obtain better PFS or OS. If future studies are considered, they 
should aim at combining several antiangiogenic agents or at targeting both blood 
and lymphatic vessels.
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2 cycles 1 2 0 3 (10%)
3 cycles 5 12 11 28 (90%)
Surgery
Yes 4 12 11 27 (87%)
No 2 2 0 4 (13%)
Adjuvant pemetrexed
Yes 5 6 8 19 (61%)
No 1 8 3 12 (39%)
Reason end of treatment
Per protocol 4 12 11 27 (88%)
PD 1 0 0 1 (3%)
AE 0 2 0 2 (6%)
Other 1 0 0 1 (3%)
Neoadjuvant pemetrexed/cisplatin: treatment given before pleurectomy. Adjuvant pemetrexed: 
pemetrexed containing therapy (monotherapy or in combination with cisplatin or carboplatin) following 
pleurectomy. PD: progressive disease. AE: adverse event.
Supplementary Table S4.2: Response rate on CT scan according to modified RECIST criteria, PFS 








PR 5 (36%) 2 (18%)  7 (28%)
SD 6 (43%) 8 (73%) 14 (56%)
PD 3 (21%) 1(9%) 4 (16%)
PFS
Median 5.8 8.3 6.4
(95% CI) (4.6–24) (6–NA) (5.0–11.9)
Events / N 13/14 11 / 11 24/25
OS
Median 22.1 18.5 21.3
(95% CI) (11.2–NA) (13.7–NA) (13.7–26.9)
Events / N 12/14 10/11 22/25 
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Supplementary Figure S4.1: Thoracoscopy of a patient treated with pemetrexed cisplatin and 
axitinib before and after therapy. 











Supplementary Figure S4.2: VEGF and VEGFR2 levels at day 1 of the 2nd and 3rd cycle presented as 
percentages compared to baseline levels. 
Soluble VEGFR2 levels decreased during axitinib treatment while VEGF levels increased. No changes 
were found in patients who didn’t receive axitinib treatment.
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Supplementary Figure S4.3: Tumour protein levels as determined by Western blot. 
The protein amount of VEGF and VEGFR2 was not affected by axitinib treatment. Activation of the 
VEGFR2 receptor was increased in the axitinib treated group; however, effect almost disappeared 
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Image-based response assessment is often used as a surrogate for the efficacy 
of a treatment in patients. The radiological response assessment in patients with 
malignant pleural mesothelioma (MPM) is notoriously difficult, despite changes 
in the scoring system, modified Response Evaluation Criteria in Solid Tumors 
(modified RECIST). The current clinical method for tumour response assessment 
in mesothelioma is the modified RECIST guideline, which calls for two linear 
measurements of tumour thickness to be summed from each of three axial sections, 
primarily in computed tomography (CT) scans. To classify patients into response 
categories, progressive disease (PD) is defined as a summed measurement increase 
larger than 20%; partial response (PR) is a summed measurement decrease of 30% 
or more, and stable disease (SD) is any measurement change between -30% and 
+20%.1-3  These changes occur between the scan at baseline or at best response.
Since the measurements are notoriously difficult to interpret and not always 
correlate with survival, an attempt was made by Labby et al. to improve this.4 
He studied 78 patients with MPM and compared the change in tumour thickness 
measurements across serial CT scans with survival. These optimal response 
categories were identified by checking all of the possible classification threshold 
combinations and maximizing the resultant concordance (C) value. The cutoff 
between PR and SD was tested at each 1% increment between -100% and 0% change 
in modified RECIST summed tumour thickness measurement.  Simultaneously, the 
cutoff between SD and PD was tested at each 1% increment between 0% and 100% 
change in summed tumour thickness measurement.  The cutoff pair that yielded 
the highest value of C was determined to be the optimum criteria. Changing the 
different response category thresholds to -64% (PR) and +50% (PD) and applying 
them to best response or first follow up scan resulted in an improved correlation 
with patient survival. These numbers were assumed to be better suited to the 
specific morphology and growth pattern of mesothelioma.4 Here we refer to this 
approach as the optimised modified RECIST.
To evaluate this recommendation, we conducted a retrospective study in an 
independent mesothelioma patient cohort using these cut-offs. With the 
approval of the institutional review boards of the Netherlands Cancer Institute 
and The University of Chicago, imaging and clinical data from 65 patients from a 
prospective open-label randomised phase 3 trial involving maintenance therapy 
with thalidomide versus active supportive care in MPM patients after first-line 
chemotherapy (NVALT 5 study) were analysed.5
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While the standard modified RECIST criteria (PR -30% and PD +20%) yielded in this 
cohort a C statistic of 0.776 with a standard error of 0.057, the Optimised RECIST 
criteria (PR -64% and PD +50%) yielded a C statistic of 0.737, which was lower than 
the initially reported C statistics of 0.855.
Out of curiosity, we optimised the NVALT data, the C statistic for the best linear 
response and this improved to 0.833 with a standard error of 0.062, when a setting 
of -41% (PR) and 100% (for PD) was used.
To assess the clinical utility of these results, the median survival times were 
evaluated based on the response categories associated with the different 
methodologies. Unfortunately, the low number of patients with a partial response 
precluded us to make a solid statement about this, but the outcome of OS in the 
three categories seemed to be all in the same range (table 5.1).
Table 5.1: Response rate, overall survival and C statistic of 3 RECIST models 
Best response model PR SD PD C statistic
Standard RECIST OS                      
-30% +20%                                       
21.5 m 25.4 m 13.8 m 0.776
Labby Optimised RECIST OS
-64% +50%
- 21.9 m 14.8 m 0.737
Optimised RECIST OS                    
-41% +100%                                   
21.5 m 20.5 m 12.9 m 0.833
The differences in outcome of the two mesothelioma studies may be due to the 
different focus of these trials. The Labby trial evaluated patients treated with 
chemotherapy in which the PR group seems to be the best represented. The 
NVALT trial was a randomised maintenance study after first-line chemotherapy and 
patients were not expect to have a PR on the study drug/active supportive care. 
Therefore, many patients eventually had progressive disease and there were only 
a few responders. This study had a higher proportion of long survivors, due to the 
selection criteria. A larger, well balanced cohort to create new RECIST criteria may 
result in improvements, giving better tools for how long patients may be treated 
with the same regimen, to optimise their survival.
We need to keep searching for better and simpler ways to evaluate the response 
in patients with malignant mesothelioma. Although the modified and Optimised 
RECIST model seemed promising, it did not lead to a superior system yet. Using a 
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larger data base, for example by using larger data sets from recent multi-center 
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Malignant pleural mesothelioma is known for its correlation between angiogenic 
factors and survival. In this chapter we focus on the background of this phenomenon 
and present the available data of studies with antiangiogenic agents. To date only 
limited signals have been found that interventions using these agents is of great 
impact of the disease. It is concluded that single agent approaches are futile and 
should be tested in combination with chemotherapy or in a multimodality setting.
Key words: VEGF receptor, bevacizumab, mesothelioma, angiogenesis




There is evidence that suggests that angiogenesis, the formation of new blood 
vessels, is an important determinant in the development and progression 
of mesothelioma. The ratio of tumour angiogenesis was initially based on 
the observation of Judah Folkman that growth of solid neoplasms is always 
accompanied by neovascularisation.1 He stated that the population of tumour cells 
and the population of capillary endothelial cells within a neoplasm may constitute 
a highly integrated ecosystem. In this ecosystem the mitotic index of the two 
cell populations may depend on each other. Tumour cells appear to stimulate 
endothelial-cell proliferation and these cells may have an indirect effect on the 
rate of the tumour growth. The rapidity with which tumour implants are able to 
stimulate cell division in neighboring capillary endothelial cells was illustrated in 
the experiments of Wood.2 Tumour cells injected into the artery supplying the 
ear chamber of a rabbit were observed as they entered the capillaries, traversed 
the capillary wall and arrived in the extravascular space, where the cells formed 
a microscopic tumour nodule. Only 18 hours after their arrival, endothelial 
cell regeneration and the formation of new capillary sprouts were observed to 
originate in neighboring post capillary venules. In 1968, it was shown that new 
capillary sprouts are elicited, even if a tumour implant is enclosed in a Millipore 
filter chamber. In the laboratory, vasoproliferative activity was consistently seen 
in hamster cheek pouches adjacent to tumour implants despite of the separation 
of the tumour and its stroma by a Millipore filter, preventing the passage of cells.3 
These studies suggested that some diffusible message was released from tumour 
to nearby endothelial cells. These cells are switched from a previously resting, 
non-regenerating, state to a rapidly dividing group of regenerating cells, capable 
of forming new capillary sprouts that can grow at the rate of 1 mm per day. It 
also has been shown that in the absence of neovascularisation, most solid tumours 
stop growing when they are 2–3 mm in size and enter a dormant though viable 
state. When tumours are removed from this dormant state to an environment 
that is highly vascularised, however, rapid neovascularisation is accompanied by 
rapid growth. And even after vascularisation has been established, the efficiency 
of diffusion of nutrients diminishes with increasing distance from each capillary. 
Probably one of the major ‘diffusible messages’ that Folkman called Tumor-
Angiogenesis factor (TAF) turned out to be vascular endothelial growth factor 
(VEGF), the most powerful endothelial cell specific mitogen associated with 
neovascularisation. The major components of the VEGF family are VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PIGF), as well as three 
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receptor tyrosine kinases, VEGFR-1, VEGFR-2, and VEGFR-3. VEGF-A, usually 
referred to simply as VEGF binds to endothelial cell VEGF Receptors. Binding to 
VEGFR-2 sets in motion a cascade of intracellular signaling pathways, leading to 
multiple functions required for sprouting neoangiogenesis, increased cell division, 
migration, changes in vascular permeability and promotion of cell survival.4 
There is strong evidence that suggests that neoangiogenesis is an important 
determinant in the development and progression of mesothelioma. Microvessel 
density (MVD), a means of assessing angiogenesis, is higher compared to other 
common tumours. Moreover, in mesothelioma a high MVD was independently 
related to poor survival, even if it was adjusted to other known prognostic factors, 
such as histological subtype and age.5-7 In preclinical models VEGF increased 
proliferation of mesothelioma and antibodies against VEGF and its receptor 
inhibited mesothelioma growth.5 In a mesothelioma population, a two- to three-
fold higher serum levels of VEGF was observed, compared to other tumours or 
healthy volunteers. Patients with MPM have also been shown to have higher VEGF 
serum levels compared with those who had been exposed to asbestos, but who not 
developed MPM.8 Angiogenesis, however, is a complex process, regulated not only 
by the VEGF family, but by a variety of other signaling proteins. Expression patterns 
of platelet-derived growth factor (PDGF) indicate that this also functions as an 
autocrine growth stimulator in the pathogenesis of malignant mesothelioma.9, 10 
Furthermore, preclinical studies have implicated fibroblast growth factor (FGF) 
and its receptor in malignant pleural mesothelioma pathogenesis, pointing to its 
role in cell proliferation and migration.11 Signaling via Src and Abl kinases have also 
been shown to be involved in MPM cell migration.12, 13
Inhibition in angiogenesis: monotherapy
Most of the earlier trials explored the effect of antiangiogenic therapies as single 
drugs, predominantly in the relapsed or recurrent setting. A few drugs were 
selected to be tested in the first-line setting in combination with platinum and 
pemetrexed. However, the outcome of these studies was generally disappointing, 
with either a lack of, or only modest clinical benefit or poor tolerability, precluding 
further development.
Sorafenib was explored in two phase 2 studies as a single agent. Sorafenib is an oral 
drug and a potent inhibitor of the RAS/RAF/MEK pathway and also targets VEGFR 
and cKit. In the CALCB 3030714 patients with mesothelioma who had received 0–1 
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prior chemotherapy regimens were treated with sorafenib 400mg orally twice 
daily continuously. The primary endpoint was partial response. Fifty-one patients 
were enrolled, 50 were evaluable and included in the analysis. Three patients had 
a partial response (6%), which lasted three, six and six months, respectively. Two of 
the 3 patients who demonstrated a response had not received prior chemotherapy. 
Twenty-seven patients (54%) had stable disease. The second study included 53 
patients after first-line therapy with platinum pemetrexed using the same dosing 
as in the CALGB trial.15 A partial response was seen in 6% of patients. Median PFS 
was 5.1 months, with 36% of patients being progression free at 6 months. This 
outcome was considered a moderate clinical activity.
Sunitinib was studied in two phase 2 studies as a single agent. Sunitinib is a 
multitargeted tyrosine kinase inhibitor, which targets VEGF receptors, PDGF 
receptors and cKit among others. The primary endpoint was in both studies the 
partial response rate. Sunitinib was given at 50 mg daily orally for 4 weeks, followed 
by a 2-week rest. The first study included 35 patients, of which 18 were treatment 
naïve. Only one partial response with a duration of 3 months was observed in a 
previous untreated patient.16 The second study did meet its primary endpoint 
and enrolled 53 progressive pretreated patients of which 51 were assessable for 
response.17 Six patients (12%) had a partial response. These patients received 
a median of 4 cycles of sunitinib, with two patients receiving 8 and 12 cycles 
respectively. Conclusion of the authors was that sunitinib had modest activity 
in mesothelioma and due to the toxicity of the drug, the dose of 50 mg daily 
was considered to high. Sunitinib was combined with pemetrexed and cisplatin 
in a phase 1 study with an expanded cohort in 10 NSCLC and 1 mesothelioma 
patients.18 It was concluded that sunitinib was not tolerated at 37.5 mg continuous 
daily dosing with standard pemetrexed and cisplatin doses. The one patient with 
mesothelioma had a partial response more than 18 weeks, the degree to which 
sunitinib was implicated in the partial response remains unclear, since pemetrexed 
and cisplatin are standard treatments for mesothelioma.
Cediranib was studied in two single arm phase 2 studies after first-line 
chemotherapy. Cediranib is an oral TKI of VEGFR-1, -2 and -3 as well as c-Kit and 
PDGFR-β and was given in a dose of 45 mg/day until progression. The SWOG 
S0509 included 54 patients, 47 evaluable patients showed a PR of 9% (4 patients), 
34% had stable disease.19 Remarkably, two patients with bulky disease showed 
tumour shrinkage of 91% and 56%, but the median progression free survival for 
the whole group was short, only 2.6 months. The drug was not well tolerated 
(fatigue, hypertension and diarrhea) and the majority of patients needed a dose 
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reduction. The university of Chicago phase 2 consortium showed the results of 51 
patients with cederanib single agent. This trial showed similar results, with a PR of 
10% and a PFS of 1.8 months in 50 evaluable patients.20 Recently the results of a 
randomised phase 2 study was published.21 Patients were treated in first line with 
platinum-pemetrexed and randomly assigned to cediranib or placebo, followed 
by maintenance cediranib or placebo. Ninety-two eligible patients were enrolled. 
Cediranib improved PFS slightly (HR 0.71; p=0.62, 7.2 vs 5.6 months) and increased 
modified RECIST v1.1 response (50% v 20%; p=0.006). Unfortunately, no significant 
difference in overall survival was observed. The cediranib toxicity profile and small 
incremental PFS benefit precluded additional development in MPM.
Vatalanib is an inhibitor of VEGF receptors, PDGF receptor, and c-KIT. It was 
studied in a phase 2 trial (CALGB 30107) in a dose of 1,250 mg/day in previously 
untreated patients.22 Forty-seven patients were enrolled and 46 patients were 
evaluable. The drug was well tolerated, but PR was only 6%. Median PFS was 4.1 
months. Further development of vatalanib as a single agent for patients with MPM 
was not warranted.
Dovitinib is an inhibitor of VEGF receptors and FGF receptors, it was studies in 
a phase 2 trial in which 12 patients were enrolled, who had previously received 
platinum-antifolate combination therapy.23 Dovitinib was administered orally at 
500 mg/day for 5 days on, 2 days off in 28-day cycles. One unconfirmed partial 
response was observed in the first part of the study. The trial was halted due to 
a combination of minimal activity with several early progression events and poor 
tolerability.
Inhibition in angiogenesis: combination therapy
In the first-line setting, antiangiogenic agents have been combined with the 
standard of care cisplatin pemetrexed. The main agents are bevacizumab, 
nintedanib and axitinib.
Bevacizumab is a monoclonal antibody that binds to VEGF-A, thereby disrupting 
the VEGF pathway. The first randomised, double blind placebo controlled trial 
combining cisplatin-gemcitabine with bevacizumab or placebo, was a phase 2 
study.24 One hundred and eight eligible patients were treated with gemcitabine 
and cisplatin in the standard dose, 53 patients were assigned to bevacizumab 
and 55 patients to placebo. Bevacizumab 15 mg/kg or placebo was administered 
intravenously on day 1 of each cycle. After 6 cycles bevacizumab or placebo was 
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continued every 21 days. The outcome was disappointing. The response rates 
were similar in both groups (24.5% and 21.8% in the placebo arm (p=0.74)). Stable 
disease occurred in 51% and 60% of patients respectively. The median PFS and 
OS were not significantly different: 6.9 vs 6.0 months and 15.6 vs 14.7 months 
respectively. The value of serum VEGF levels at baseline in 56 patients was 
examined in this study. The median plasma VEGF levels of 144 pg/mL were indeed 
significantly higher than those observed in phase 3 trials in non-small-cell lung 
cancer (38.7 pg/mL)25 and colorectal cancer (44 pg/mL), confirming the importance 
of angiogenesis in this tumour.26 Neither baseline VEGF level or mean log VEGF 
values could discriminate responders from non-responders. Higher baseline log 
VEGF levels, however, were prognostic for a worse PFS and OS. For OS the death 
rate increased by a factor 1.37 for each doubling of the VEGF level. In patients with 
baseline VEGF levels at or below the median, PFS (p=0.043) and OS (p=0.028) were 
significantly better for bevacizumab than for the placebo arm.
Two phase 2 studies first explored the effect of adding bevacizumab to cisplatin 
and pemetrexed in chemo naïve patients.27, 28 They were both single arm trials with 
respectively 76 and 53 patients. The studies failed to achieve their primary endpoint 
of improving PFS compared to historical controls of chemotherapy alone. However, 
the large French open label, randomised phase 2/3 study that added bevacizumab 
to cisplatin and pemetrexed in chemo naïve patients did show a beneficial effect.29 
A total of 448 patients were treated with up to 6 cycles of standard treatment 
pemetrexed and cisplatin and were randomised between bevacizumab 15 mg/kg 
or chemotherapy alone. Subsequent maintenance bevacizumab was permitted. 
Not only PFS, but also OS was statistically increased in the bevacizumab arm: 
median 18.8 months versus 16.1 month (HR 0.77, 95% CI 0.62–0.95). The positive 
effect of the bevacizumab arm could not be explained by post-study treatment. 
This was even given less frequently in the bevacizumab arm 62% versus 72% in 
the standard chemotherapy arm. There was no crossover to bevacizumab. Serum 
VEGF baseline concentrations were assayed in 372 (83%) patients, representative 
for the whole study population. Again, high VEGF concentrations were associated 
with worse PFS and OS. The interaction between treatment group and VEGF serum 
concentration was not significant.
The reason why the outcome in the MAPS study was positive in contrast to the 
study with gemcitabine, may lay in the backbone of the treatment. Subsequent 
studies have shown that adding bevacizumab to a gemcitabine backbone does 
not improve survival in either pancreatic or lung cancer25, 30 and preclinical data 
suggest a negative interaction between bevacizumab and gemcitabine.31 Some 
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cytotoxic agents, but not gemcitabine, stimulate angiogenesis and tumour 
regrowth by mobilizing circulating progenitors from bone marrow. VEGF inhibitors 
may augment chemotherapy by blunting this effect. According to this hypothesis, 
for optimal activity, bevacizumab should be combined with agents that can rapidly 
induce these pro-angiogenic cells. 
Nintedanib is a multitargeted angiokinase inhibitor, with activity against VEGF 1, 2 
and 3, PDGFR and FGF receptors, among others. It was hypothesized that, in contrast 
to bevacizumab that only inhibits VEGF, this multitargeted approach could enhance 
efficacy. Nintedanib was studied in the phase 2/3 LUME-Meso trial in patients with 
epithelioid or biphasic MPM in a first-line setting.32 Patients were randomised 
to nintedanib, 200 mg twice daily, or placebo in combination with cisplatin 
pemetrexed for up to six cycles, followed by nintedanib or placebo maintenance. 
A total of 87 patients were enrolled, and the outcome was positive. Addition of 
nintedanib to pemetrexed cisplatin improved PFS (median 9.4 vs 5.7 months; HR 
0.54; 95% CI 0.33–0.87; p=0.010) and was associated with a trend toward improved 
OS (median 18.3 vs 14.2 months; HR 0.77; 95% CI 0.46–1.29; p=0.319) compared 
to placebo. The positive effect was not clearly seen in the subgroup analysis in 
the patients with biphasic histology. Therefore, the phase 3 trial was continued 
with only patients with epithelial subtype MPM.33 In this trial 458 patients were 
treated under the same conditions. Unfortunately, these encouraging findings 
could not be confirmed. The primary endpoint PFS was not met, median PFS for 
nintedanib versus placebo was 6.8 versus 7.0 months (HR [95% CI] 1.01 [0.79–1.30]; 
p=0.914). Median OS at the interim analysis for nintedanib versus placebo was 14.4 
versus 16.1 months (HR [95% CI] 1.12 [0.79–1.58]; p=0.538). The study has been 
discontinued as per the study protocol.
Axitinib is an inhibitor of VEGFR-1, -2 and -3, PDGFR and c-Kit and was tested in an 
open label, randomised phase 2 study in combination with cisplatin pemetrexed 
in treatment naïve mesothelioma patients.34 In total 20 patients received 
chemotherapy and axitinib in a dose of 5 mg tablets twice daily from day 2 until 
day 19. Eleven patients received chemotherapy only. This imbalance occurred 
because the first six consecutive patients all received chemotherapy and axitinib, 
being part of a lead-in cohort. The remaining 26 patients were randomised. 
Adding axitinib to standard chemotherapy did not improve results. There was no 
difference in the number of responders between the groups (p=0.85). Complete 
responses were not observed. The rates of partial response (PR) and stable disease 
(SD) in the two arms were respectively 36% and 43% in the axitinib arm and 18% 
and 73% in the chemotherapy only arm. Although the sample size was too small to 
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draw clear conclusions, a median PFS of 5.8 months (95% CI 4.6–24) in the axitinib 
group and 8.3 months (95% CI 6–NA) in the chemotherapy only group (p=0.86) was 
not promising. In this study all patients received a thoracoscopy before start of 
treatment. After 3 cycles of therapy, a second thoracoscopy was carried out for a 
palliative pleurectomy and biopsies in all 11 patients treated with chemotherapy 
only and in 16 patients in the axitinib group. The design of the study was to 
correlate a possible clinical effect of axitinib to a biomarker. Therefore, intra-
tumour changes on vascularisation were explored. The lack of positive result in 
response rate and PFS did not allow identifying such a biomarker. However, in the 
group of patients receiving only pemetrexed and cisplatin, there was a significant 
increase of microvessel density in the tumour biopsies (p<0.001). In addition, the 
number of mature blood vessels (p=0.01) increased after therapy. In the axitinib 
group the amount of microvessel density and mature blood vessels remained at 
the same level during the treatment. In the axitinib group, serum VEGFR2 levels 
decreased during treatment, due to binding of the axitinib to the receptor. Instead, 
VEGF levels increased during treatment, probably resembling a rebound effect.
Inhibition in angiogenesis: switch maintenance therapy
Thalidomide is an oral drug that inhibits the release of VEGF and basic FGF 
production. It has shown activity in a single arm phase 2 study, were 40 patients 
were treated with pemetrexed and a platinum combination and if they had a 
partial response or stable disease after 4–6 course of chemotherapy, they could 
switch to thalidomide until progression or intolerable toxicity.35 Twenty-five % of 
patients had more than 6 months stabilization on the drug. This was reason to 
continue to an open label, randomised phase 3 study in which 222 patients were 
treated, 111 in the thalidomide arm, with a dose of 200 mg per day and 111 in the 
active supportive care arm.36 Primary endpoint was to determine a more than 50% 
increase in time to progression, but unfortunately this was not met. Median time 
to progression in the thalidomide arm was 3.6 months (95% CI 3.2–4.1) compared 
with 3.5 months (2.3–4.8) in the active supportive care group (HR 0.95, 95% CI 
0.73–1.20, p=0.72). There was also no difference in median overall survival. This 
was 10·6 months (95% CI 8.1–13.6) in the thalidomide group and 12.9 months 
(10.4–16.4) in the active supportive care group (HR 1.2, 95% CI 0.9–1.6, p=0.21).
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Conclusions and future directions
Since the development of inhibitors of angiogenesis, a substantial number of 
studies has been performed in the hope that this new strategy would ameliorate 
the prognosis of patients with MPM. Many multitargeted agents, that all had in 
common that the VEGF receptor was blocked, were used in second or further 
lines, but they usual showed no or limited activity and sometimes even substantial 
toxicity. The available clinical evidence even seemed to call into question the actual 
in vivo importance of these targets for MPM and the ability of the current agents 
to effectively disrupt these targets and turn this effect into a clinical benefit for 
the patient. However, in first-line studies, positive results have been alternated 
with negative results. With bevacizumab in combination with pemetrexed and 
cisplatin a positive result for PFS as well as OS was achieved for the first time in a 
large randomised study, but not with gemcitabine and cisplatin. Promising phase 
2 data with nintedanib could not be confirmed in the subsequent phase 3 trial that 
added nintedanib to pemetrexed and cisplatin. To maximise the effect of adding 
bevacizumab to pemetrexed and cisplatin the key may be in finding validated 
predictive biomarkers, but until now such biomarkers are not identified. The next 
step may be combining antiangiogenic therapy with immunotherapy. Angiogenic 
factors have roles in both blood vessel formation and regulation of the immune 
system. High levels of VEGF can inhibit dendritic cell functions and VEGF has 
been shown to directly modulate T-cell proliferation, migration and activation in 
preclinical studies.37 It has been suggested that combining antiangiogenic agents 
with immunotherapy may produce synergistic effects. As an illustration, in the 
randomised phase 3 study in patients with first-line advanced NSCLC, the addition 
of bevacizumab and the PD-L1 inhibitor atezolizumab to chemotherapy was 
more effective than the addition of either agent alone.38 This hypothesis is now 
being examined in mesothelioma patients in several studies. In a phase 1 study 
nintedanib is combined with the PD-1 inhibitor pembrolizumab (NCT02856425) also 
including MPM patients and a phase 2 study is underway evaluating bevacizumab 
and atezolizumab in MPM patients (NCT03074513). A randomised phase 3 
trial comparing atezolizumab plus bevacizumab and standard chemotherapy 
(carboplatin and pemetrexed) versus bevacizumab and standard chemotherapy as 
first-line treatment for advanced malignant pleural mesothelioma (NCT03762018) 
is now recruiting.
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Discussion and future perspectives
Malignant mesothelioma is a tumour arising from the mesothelial lining of the 
pleura, peritoneum, pericardium and tunica vaginalis. Pleural mesothelioma is the 
most common of these, accounting for approximately 90% of the disease.
The association between mesothelioma and asbestos exposure is well established 
and is confirmed in more than 80% of cases. In rare cases germline BAP1 mutations 
give rise to a tumour predisposition syndrome with increased risk of developing 
melanoma, mesotheliomas and renal cell carcinomas.  
Malignant pleural mesothelioma (MPM) is notoriously refractory to different 
treatment modalities. There are several treatment options though, that in general 
do not lead to a curation. These involve in selected cases surgery alone; surgery 
in combination with chemotherapy and/or radiotherapy or chemotherapy alone. 
Several kinds of biologicals and immunotherapies have been or are currently 
under investigation. Until recently, chemotherapy was considered to be the 
standard treatment for patients with mesothelioma. Two large phase 3 studies 
have shown that the combination of cisplatin with an antifolate drug (pemetrexed 
or raltitrexed) significantly improved both response rate and median overall 
survival compared with cisplatin alone with a survival benefit of 2.8 months in the 
first-line setting.1, 2 More recently, it was shown that the addition of bevacizumab 
to cisplatin and pemetrexed was of benefit in a randomised phase 3 trial (MAPS).3 
The primary outcome, overall survival, was significantly better for the group of 
patients randomised to the bevacizumab arm. In both arms, a much better median 
overall survival was observed compared to the historic data, with 16.1 month for 
cisplatin pemetrexed alone and 18.8 months for the experimental arm. However, 
an OS benefit of 2.7 months with a HR of 0.77 (p=0.01) was not enough to fulfil the 
required criteria for a general acceptance in the European countries. Therefore, 
this drug combination was not registered in the Netherlands as the new standard 
of care. Very recently, on October 2, 2020, the Food and Drug Administration 
approved the combination of nivolumab plus ipilimumab as first-line treatment 
for adult patients with unresectable malignant pleural mesothelioma, a major 
breakthrough. Hopefully, the rest of the world will follow soon. Efficacy was 
investigated in CHECKMATE-743 (NCT02899299), a randomised, open-label trial in 
patients with unresectable malignant pleural mesothelioma and no prior anticancer 
therapy. Patients were randomised to receive either nivolumab and ipilimumab 
for up to 2 years (n=303) or 6 cycles of combination chemotherapy with cisplatin 
or carboplatin plus pemetrexed (n=302). The trial demonstrated a statistically 
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significant improvement in overall survival (OS) for patients treated with nivolumab 
plus ipilimumab compared with those who received chemotherapy. Median 
OS was 18.1 months versus 14.1 months (HR 0.74; p=0.002). There was a larger 
magnitude of benefit found in the non-epithelioid subgroup. Median OS was 18.7 
months for epithelioid patients (HR 0.86; 95% CI 0.69–1.08) and 18.1 months for 
non-epithelioid patients (HR 0.46; 95% CI 0.31–0.68) with the dual immunotherapy 
combination compared to 16.5 months and 8.8 months, respectively.
Despite the development of many other trials with different compounds in the 
recent years, no other approved treatments have been identified to date yet. 
There is evidence that suggests that neoangiogenesis is an important factor in 
the development and progression of mesothelioma. In preclinical models vascular 
endothelial growth factor (VEGF) increased proliferation of mesothelioma and 
antibodies against VEGF and its receptor inhibited mesothelioma growth.4 A 
two-to three fold higher serum levels of VEGF has been observed in patients 
with mesothelioma, compared to other malignancies or healthy volunteers. 
This suggests an autocrine growth effect of the tumour. Furthermore, a higher 
microvessel density (MVD) has been observed in mesothelioma biopsies compared 
to other malignancies. A high MVD was independently related to poor survival, 
even when adjusted for other known prognostic factors such as histological 
subtype and age.4, 5 These observations led to the testing of several kinds of 
antiangiogenic drugs in mesothelioma, used as a monotherapy or in combination 
with chemotherapy and made this category of drugs the base of this thesis.
Along the use of the antiangiogenic drugs thalidomide and axitinib in this thesis, 
we also explored new response measurements in mesothelioma patients. Since 
the outcome overall survival is not always reliable in small (non-randomised) trials, 
image-based response assessment is often used as a surrogate for the efficacy of 
a treatment in patients. For that reason, the most relevant response classification 
criteria would be those that correlate the radiologic assessment with overall 
survival of individual patients. In the past, the original Response Evaluation Criteria 
in Solid Tumors (RECIST) classification categorised progressive disease (PD) as an 
increase in the bidimensional measurement of 25% or more and a partial response 
(PR) as a bidimensional measurement decrease of 50%.6 Later on, these two-
dimensional measurements were converted to one-dimensional measurements 
using an assumption of spherical volume geometry, leading to the current RECIST 
classification criteria.7, 8 However, mesothelioma is a malignancy of the pleural 
lining that is separating the lungs and the thoracic wall and therefore is usual an 
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aspherical disease. Furthermore, the thickening of the pleura may often be subtle 
and therefore not reproducible and the surface of the tumour is often large. 
These facts casted some doubt on the applicability of these criteria on 
mesothelioma and this lead to the modified RECIST guidelines, which calls for 2 
linear measurements of tumour thickness to be summed from each of three axial 
sections, primarily in computed tomography (CT) scans.9, 10 In the past, theoretical 
geometric models were developed and these indicated that if the definition 
of stable disease (SD) were broader it would more closely approximate the 
corresponding volume changes seen in tumours of spherical morphology.11 In an 
attempt to improve this scoring system, a study was performed focussing on the 
growth changes of the tumour in time.12 Changing the different response category 
thresholds to -64% (PR) and +50% (PD) and applying them to best response or 
first follow up scan resulted in an improved correlation with patient survival. The 
question whether these optimised modified RECIST criteria would hold in another 
cohort was not confirmed yet.
The aim of this thesis was to improve progression free survival and overall survival in 
mesothelioma patients with antiangiogenic drugs and increase the understanding 
of the mechanism action of VEGF inhibitors in humans. Furthermore, the reliability 
of the newly proposed optimised modified RECIST criteria were tested in an 
independent mesothelioma cohort.
In chapter 2, we conducted a systematic review of the current literature at that time 
for the activity and toxicity of second-line treatment. The results were presented 
according to the class of drugs: chemotherapy and targeted or biological agents.
In chapter 3 we show the results of a large, open-label phase 3 maintenance study 
that randomised between thalidomide versus active supportive care after first-
line chemotherapy in 222 mesothelioma patients.13 The study was performed in 8 
Dutch and 4 Australian centers. Thalidomide is an oral drug and has an excellent 
bioavailability. Besides immunomodulatory and anti-inflammatory properties, it 
also inhibits angiogenesis. It was not until 2009 that it was shown that thalidomide 
blocked the filopodial outgrowth of endothelial cells and that proliferation and 
migration and forming of vascular tubes was prevented.14 This explained the 
serious congenital birth defects observed in the late fifties in pregnant woman 
who used the drug as a non-barbiturate with sedative and anti-emetic activity. 
In our study, we could not show any benefit in the time to progression when 
thalidomide maintenance therapy was given. The median time to progression in 
the thalidomide group was 3.6 months compared to 3.5 months in the control 
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arm (HR 0.95; 95% CI 0.73–1.20; p=0.72). The median overall survival was also not 
different with 10.6 months in the thalidomide arm and 12.9 months in the control 
arm (HR 1.2; 95% CI 0.9–1.6; p=0.21). 
The study also included a voluntary biomarker research part. Serum samples were 
collected prospectively in 73 patients, which were tested for VEGF, bFGF, IL6, Cyfra 
21.1 and SMRP expression. The demographic profiles of patients with and without 
biomarker samples were comparable. Of these markers, only IL6 and Cyfra 21.1 were 
prognostic for survival, irrespective of treatment with thalidomide. Patients with 
both reduced baseline interleukin 6 and Cyfra 21.1 values had improved prognosis, 
with a median overall survival of 17.1 months (95% CI 13.4–24.5) compared to 7.6 
months (6.7–12.2) for patients with an increased baseline interleukin 6 and Cyfra 
21.1. Although SMRP seems to be a promising tumour marker in mesothelioma,15 
there was no association found with survival in this cohort. A possible reason for 
the absence of prognostic value may be found in the time of measurement and 
the eligibility criteria of the patients. Samples were taken after completion of the 
first-line treatment and only in patients who had not progressed. Since SMRP is 
suggested to be associated with the status (volume) of disease, as it performs 
better in advanced disease, the possible value of SMRP as a prognostic marker 
could have been underestimated in our study. 
The negative outcome of the NVALT 5 study is in line with 2 other large randomised 
studies that studied (continuous) maintenance treatment with an antiangiogenic 
compound after first-line chemotherapy. 
A randomised, double blind, placebo controlled phase 2 trial tested the 
combination of cisplatin-gemcitabine with bevacizumab or placebo.16 Bevacizumab 
is a monoclonal antibody that binds to VEGF-A, thereby disrupting the VEGF 
pathway. One hundred and eight eligible patients were treated with gemcitabine 
and cisplatin in the standard dose and randomised to bevacizumab or placebo in 
a 1 to 1 ratio. The median PFS and OS were not significantly different: 6.9 vs 6.0 
months and 15.6 vs 14.7 months respectively.
The second study was the LUME-Meso trial.17 Patients with epithelial subtype 
MPM were randomised to nintedanib, 200 mg twice daily, or placebo in 
combination with cisplatin pemetrexed for up to six cycles, followed by nintedanib 
or placebo maintenance. Nintedanib is a multitargeted angiokinase inhibitor, 
with activity against VEGF 1, 2 and 3, PDGFR and FGF receptors, among others. 
It was hypothesised that this multitargeted approach could enhance efficacy. 
Unfortunately, the encouraging findings of the phase 2 part of this phase 2/3 trial 
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could not be confirmed. The primary endpoint PFS was not met. Median OS at the 
interim analysis for nintedanib versus placebo was 14.4 versus 16.1 months (HR 
[95% CI] 1.12 [0.79–1.58]; p=0.538). The study was discontinued as per the study 
protocol.
The large open label, randomised phase 2/3 study that added bevacizumab to 
cisplatin and pemetrexed in chemo naïve patients (MAPS) is the only study that did 
show a beneficial effect.3 A total of 448 patients were treated with up to 6 cycles 
of standard treatment pemetrexed and cisplatin and were randomised between 
bevacizumab (15 mg/kg) or chemotherapy alone. Subsequent maintenance 
bevacizumab was permitted. Not only PFS, but also OS increased significantly in 
the experimental arm. The effect was modest: median 18.8 months versus 16.1 
months (HR 0.77, 95% CI 0.62–0.95). 
The reason why the MAPS study was positive in contrast to the study with 
gemcitabine, may be related to the backbone of the treatment. Subsequent 
studies have shown that adding bevacizumab to a gemcitabine backbone does not 
improve survival in either pancreatic or lung cancer18, 19 and preclinical data suggest 
a negative interaction between bevacizumab and gemcitabine.20 Some cytotoxic 
agents can stimulate angiogenesis and tumour regrowth by mobilizing circulating 
progenitors from bone marrow. This seems not to be the case for gemcitabine. 
VEGF inhibitors may augment the cytotoxic effect of some chemotherapy 
regimen by blunting this effect. According to this hypothesis, for optimal activity, 
bevacizumab should be combined with agents that can rapidly induce these pro-
angiogenic cells. 
In chapter 4 we discuss the additional effect of the VEGF TKI axitinib, a potent 
oral inhibitor of mainly the tyrosine kinase receptors for VEGF, to cisplatin and 
pemetrexed combining clinical and translational outcomes in a small randomised 
phase 2 study. Response evaluation was not only achieved by a CT-scan, but a 
second thoracoscopy after three courses of systemic therapy was performed to 
study intra-tumour changes. Based on the mechanism of action of axitinib, we 
focused on the changes in vascularisation in the paired intraindividual tumour 
biopsy samples. 
Since axitinib was not previously tested in mesothelioma with this chemotherapy 
regimen, the study design included a lead in period of 6 patients to test the 
feasibility of the combination. In total, twenty patients received chemotherapy 
and axitinib and 11 patients chemotherapy alone.
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We demonstrated that performing a second thoracoscopy in a patient after initial 
treatment was successful. Following our study, this model has been used successfully 
in other mesothelioma studies that focused on immunotherapy in our group.21, 22 
The clinical outcome of the study was negative. Although the partial response rate 
was higher in the axitinib group, 36% versus 18%, this did not translate to a longer 
progression free survival. The median OS was 18.9 months (95% CI 11.2–NA) in the 
axitinib group and 18.5 months (95% CI 13.7–NA) in the chemotherapy-only group 
(p=0.78). These results are quite long for both groups, but can be explained by a 
selection bias. Patients in this study had to have a good performance status to be 
candidates for a pleurectomy during the second thoracoscopy. 
In the translational research part, we showed that axitinib treatment efficiently 
prevented tumour neoangiogenesis and improved vessel maturation compared 
to tumour biopsies of patients treated with chemotherapy alone. There was a 
significant increase in microvessel density in the tumour biopsies after treatment 
with pemetrexed and cisplatin compared to biopsies before treatment (p<0.0001). 
In addition, the number of immature blood vessels increased after chemotherapy 
in this group (p=0.0003). In contrast, in the axitinib group, microvessel density and 
the number of mature blood vessels remained the same after treatment. Analysis of 
mRNA expression showed that most of the angiogenic ligands and their receptors 
(FGF2, PDGFβ and to a lesser extent PGF and their corresponding receptors) 
were increased after treatment with axitinib. This might reflect a rebound effect 
caused by stopping axitinib treatment for safety reasons, 5 days before the second 
thoracoscopy. It is also possible that increased mRNA expression of angiogenic 
growth factors and their receptors were a compensatory reaction to the inhibition 
of the VEGF signaling axis by axitinib. The importance of not only controlling VEGF/
VEGFR2 signaling, but also of balancing other signaling pathways was underlined 
by the finding that increased mRNA expression of vascular (PDGFRβ and FLT1/
VEGFR1) and lymphatic (FLT4/VEGFR3) growth factor receptors was strongly 
correlated with worse prognosis; partial regression was only observed in patients 
with lowest expression levels. These correlations of (lymph)angiogenic factors with 
clinical outcome suggest that vascular alterations and/or neovessel formation play 
an important role in mesothelioma. However, we have to keep in mind that this 
study demonstrated that only reducing MVD and increasing the maturity of blood 
vessels was not sufficient to obtain better PFS or OS.
In chapter 5 we focused on the possible implementation of new optimised 
modified RECIST criteria. 
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In previous work by Labby et al., 78 mesothelioma patients were analysed 
comparing the outcome of serial CT scans with survival.12 The aim of that study 
was to determine the optimal correlation between response classification and 
overall survival for MPM patients.
In this study C statistic was used as a determinant for the success of the model. 
An analysis based on the C statistic is an analysis of the discriminatory value of a 
test, namely the ability of the test to be able to distinguish between high and low 
risk people or to make a distinction, compared to mere coincidence. For binary 
outcomes, the C statistic corresponds to the area under the curve (AUC) of the 
Receiver Operating Characteristic curve (ROC). The area under the curve indicates 
the accuracy of the test: 1 is a perfect test and 0.5 is a worthless test which detects 
as many correct positives as false positives. When the C statistic is higher than 0.7, 
the models are generally regarded as acceptable and with a C statistic >0.8, highly 
acceptable.
The optimal response categories were identified by checking all of the possible 
classification threshold combinations and maximising the resultant concordance 
(C) value. The cutoff pair that yielded the highest value of C was determined to be 
the optimum criteria. Changing the different response categories to -64% (PR) and 
+50% (PD) compared to best response or first follow up scan, resulted in an improved 
outcome of response classification criteria.12 To evaluate this recommendation, we 
conducted a retrospective study in an independent mesothelioma patient cohort, 
a subset of patients of the NVALT 5 study, using these cut-offs.23 The results could 
not confirm the promising results for the initial paper in our patient cohort. While 
the standard modified RECIST criteria (PR -30% and PD +20%) yielded in this cohort 
a C statistic of 0.776 with a standard error of 0.057, the Optimised RECIST criteria 
(PR -64% and PD +50%) yielded a C statistic of 0.737, which was lower than the 
initially reported C statistics of 0.855. 
The differences in outcome of the two mesothelioma studies may be due to the 
different focus of these trials. The Labby trial evaluated patients treated with 
chemotherapy in which the PR group seems to be the best represented. The 
NVALT trial was a randomised maintenance study after first-line chemotherapy 
and patients were not expect to have a PR on the study drug/active supportive 
care. Our study had a higher proportion of long survivors, due to the selection 
criteria. A larger, well-balanced cohort to create new RECIST criteria may result in 
improvements, giving better tools for how long patients may be treated with the 
same regimen, to optimise their survival.
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In chapter 6 an up to date review is given of all the studies that were published in 
recent years, concerning inhibitors of angiogenesis in mesothelioma.
Perspectives
The first landmark study on tumour antiangiogenesis was published in 1971 by 
Folkman.24 He stated that the growth of solid neoplasms is always accompanied by 
neovascularisation. Since then the observation was made that patients with MPM 
had high circulating VEGF levels, suggesting an autocrine effect of the tumour. 
It was shown that the tumour itself had a high microvessel density in relation to 
other tumours and that MVD was independently related to poor survival. These 
considerations led to the development of many antiangiogenic drugs. Over the 
last 3 decades, many of these drugs have been tested in clinical trials in MPM 
patients, as a monotherapy or in combination with chemotherapy, but this did not 
lead to a break through in the care of MPM patients and sometimes even lead to 
substantial toxicity. Some of the drugs made it to phase 3 trials, but none of them 
were registered as a new indication for MPM. 
How should we move forward? 
We have to keep in mind that mesothelioma is a rare disease. The incidence is low, 
varying from 2–30/100,000 inhabitants worldwide. In the Netherlands, about 600 
new cases are diagnosed each year. Despite of these relatively low numbers, the 
socio-medical implications are huge and the growing incidence in the developing 
world is alarming. The need for better treatments are high and we have to keep 
searching for better drug combinations. With a low incidence disease and large 
numbers of candidate drugs, small studies need to provide efficiently valuable 
information. When testing small number of patients, it is of key importance to 
include a standard treatment arm in the randomisation. This is the most efficient 
way to quickly gather relative unbiased data for drug-screening purposes. By 
adding translational research in search for valuable biomarkers we may find signals 
to better support for the use of a new drug. The fact that we could demonstrate 
in our axitinib study that only reducing MVD and increasing the maturity of blood 
vessels was not sufficient to obtain better PFS or OS in patients, favors this 
statement.
The next step may be combining antiangiogenic therapy with immunotherapy. 
The aforementioned randomised phase 3 study with nivolumab ipilimumab 
Discussion and future perspectives
137
7
versus chemotherapy in the front line setting recently lead to approval by the 
FDA of the immunotherapy combination (NCT02899299).The results of the large 
randomised, placebo controlled, phase 3 trial with nivolumab in the salvage setting 
(NCT03063450) and the  randomised phase 3 trial investigating the efficacy of 
pembrolizumab versus gemcitabine or vinorelbine in relapsed MPM patients 
(NCT02991482) showed that immunotherapy was better than best supportive 
care, but not better than chemotherapy. 
Why should we combine antiangiogenic therapy with immunotherapy? Angiogenic 
factors have roles in both blood vessel formation and regulation of the immune 
system. High levels of VEGF can inhibit dendritic cell functions and VEGF has 
been shown to directly modulate T-cell proliferation, migration and activation in 
preclinical studies.25 It has been suggested that combining antiangiogenic agents 
with immunotherapy may produce synergistic effects. As an illustration, in the 
randomised phase 3 study in patients with first-line advanced NSCLC, the addition 
of bevacizumab and the PD-L1 inhibitor atezolizumab to chemotherapy was more 
effective than the addition of either agent alone.26 This hypothesis is now being 
examined in patients with mesothelioma in several studies. In a phase 1 study also 
including MPM patients, nintedanib is combined with the PD-1 inhibitor pembroli-
zumab (NCT02856425) and a phase 2 study is underway evaluating bevacizumab 
and atezolizumab in MPM patients (NCT03074513). A randomised phase 3 
trial comparing atezolizumab plus bevacizumab and standard chemotherapy 
(carboplatin and pemetrexed) versus bevacizumab and standard chemotherapy as 
first-line treatment for advanced malignant pleural mesothelioma (NCT03762018) 
is now recruiting, as well as pembrolizumab plus lenvatinib in second-line and 
third-line malignant mesothelioma patients (NCT04287829). 
In conclusion, malignant pleural mesothelioma remains to be a nearly invariably 
lethal tumour. Due to the long latency period and the fact that the use of 
asbestos is not prohibited worldwide, mesothelioma will continue to be a health 
hazard. Despite all our efforts to improve survival with combinations of surgery, 
radiotherapy and all kind of drugs, we have barely been able to succeed yet. We 
should keep in mind that the most effective strategy to decrease the incidence of 
mesothelioma is to ban the use of asbestos and ensure regulations to disassemble 
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Maligne pleuraal mesothelioom (MPM), in de volksmond ook wel asbestkanker 
genoemd, is een ernstige ziekte en weinig gevoelig voor verschillende behande-
lingsmodaliteiten. De prognose is in het algemeen somber. 
Meer dan 15 jaar geleden toonde een groot fase 3 onderzoek aan dat de combi-
natie van cisplatin met pemetrexed als eerstelijnsbehandeling de mediane over-
leving significant verbeterde. Sindsdien zijn er veel studies uitgevoerd met een 
scala aan nieuwe medicijnen. Ondanks al deze inspanningen werden tot voor kort 
geen nieuwe behandelingen voor MPM geregistreerd. Heel recent is namelijk wel 
gebleken dat immuuntherapie, in de vorm van ipilimumab nivolumab, beter is dan 
chemotherapie en dit zal binnenkort de nieuwe standaard behandeling worden.
Er zijn aanwijzingen dat neo-angiogenese, dat wil zeggen de vorming van nieuwe 
vaten door de tumor zelf gestimuleerd, een belangrijke factor is bij de ontwik-
keling en progressie van het mesothelioom. In preklinische modellen verhoogde 
de vasculaire endotheliale groeifactor (VEGF) de groei van het mesothelioom en 
antilichamen tegen VEGF en de receptor hier van, remde de groei van het meso-
thelioom. Bovendien bleek MPM een hogere microvaatdichtheid (MVD) te hebben 
dan andere veel voorkomende tumoren. Bij biopsieën van de tumor bij mesothe-
lioom patiënten was een hoge MVD onafhankelijk gerelateerd aan een slechte 
overleving, zelfs als deze was gecorrigeerd voor andere bekende prognostische 
factoren zoals histologisch subtype en leeftijd. Anti-angiogene geneesmiddelen 
leken een veelbelovende stap naar verbetering van de behandeling van MPM en de 
ontwikkeling van vele mesothelioom trials met anti-angiogene geneesmiddelen, 
die soms als  monotherapie werden ingezet of soms in combinatie met chemo-
therapie volgende hierop. Anti-angiogene geneesmiddelen zijn de basis van dit 
proefschrift.
Het doel van dit proefschrift was om de progressievrije overleving (PFS) en de 
totale overleving (OS) bij mesothelioompatiënten met anti-angiogene geneesmid-
delen te verbeteren en het begrip van het werkingsmechanisme van VEGF-rem-
mers bij mensen te vergroten. Hiervoor zijn twee onderzoeken opgezet, één met 
het medicijn thalidomide en één met het medicijn axitinib. Bovendien werd de 
betrouwbaarheid van een nieuw voorgesteld RECIST-model (Respons Evaluatie 
Criteria In Solide Tumoren), dat wordt gebruikt bij het beoordelen van respons op 




Om de algemene kennis van de behandeling van mesothelioom te vergroten, 
hebben we een systematisch review van de literatuur voor tweedelijnsbehande-
lingen uitgevoerd en een up-to-date review geschreven van alle studies die de 
afgelopen jaren zijn gepubliceerd, die angiogenese remmers in het mesothelioom 
onderzochten.
In dit proefschrift delen we de resultaten van de grote fase 3 studie, waarbij 
gerandomiseerd werd tussen thalidomide en palliatieve zorg, na eerstelijnsbe-
handeling met cisplatin en pemetrexed. Er deden 222 mesothelioompatiënten 
aan mee. Thalidomide wordt gegeven in tabletvorm. Helaas was er geen voordeel 
in de tijd tot progressie door toevoeging van thalidomide na chemotherapie. De 
mediane tijd tot progressie in de thalidomidegroep was 3,6 maanden vergeleken 
met 3,5 maanden in de controle-arm (HR 0,95; 95% betrouwbaarheidsinterval [BI] 
0,73–1,20; p=0,72). De mediane totale overleving was ook niet verschillend met 
10,6 maanden in de thalidomidegroep en 12,9 maanden in de controle-arm (HR 
1,2; 95% BI 0,9–1,6; p=0,21).
De studie omvatte ook een biomarker onderzoek . Serummonsters werden vrij-
willig, prospectief verzameld bij 73 patiënten en getest op VEGF-, bFGF-, IL6-, 
Cyfra 21.1- en SMRP-expressie. IL6 en Cyfra 21.1 bleken prognostisch voor over-
leving, onafhankelijk van de behandelarm. Patiënten met zowel verlaagde inter-
leukine 6- als Cyfra 21.1-baselinewaarden hadden een betere prognose, met een 
mediane totale overleving van 17,1 maanden (95% BI 13,4–24,5) vergeleken met 
7,6 maanden (6,7–12,2) voor patiënten met verhoogde baseline waarden. Hoewel 
SMRP eerder een veelbelovende tumormarker leek te zijn bij mesothelioom, werd 
er in dit cohort geen verband gevonden met overleving. Een mogelijke verklaring 
voor het ontbreken van een prognostische waarde in onze studie kan worden 
gevonden in het moment van meten en de inclusiecriteria van de studie. Bloed-
monsters werden genomen na voltooiing van de eerstelijnsbehandeling en alleen 
bij patiënten die niet progressief waren. Er werd eerder gesuggereerd dat SMRP 
beter voorspelt bij een heel uitgebreide tumor en aangezien patiënten in onze 
studie net een behandeling met chemotherapie achter de rug hadden, kan het zijn 
dat de waarde van SMRP als prognostische marker onderschat is.
We presenteren ook een kleinere gerandomiseerde fase 2-studie die het effect 
van de VEGF-tyrosine kinase remmer axitinib onderzocht als die wordt toege-
voegd aan de behandeling met cisplatin en pemetrexed. Axitinib is een krachtige 
remmer van voornamelijk de tyrosine kinase receptoren van VEGF. Het wordt ook 




van een CT-scan, maar na drie kuren werd een tweede thoracoscopie verricht om 
veranderingen in de tumor van elke individuele patiënt te bestuderen. Uiteraard 
werd hier gekeken naar de vascularisatie van de tumor. 
Aangezien axitinib niet eerder was gegeven bij mesothelioom patiënten met dit 
behandelingsschema, omvatte de onderzoeksopzet een aanloopperiode om de 
verdraagzaamheid van de nieuwe combinatie te testen. Hierbij werden in eerste 
instantie 6 patiënten behandeld die allemaal axitinib kregen. Daarna werd er 
gerandomiseerd. Uiteindelijk kregen twintig patiënten chemotherapie en axitinib 
en 11 patiënten alleen chemotherapie.
We hebben in deze studie aangetoond dat het uitvoeren van een tweede thoraco-
scopie na behandeling met 3 kuren succesvol was. Na onze studie is dit model ook 
met succes gebruikt bij andere mesothelioomstudies in onze groep.
Het klinische resultaat van de studie was negatief. Hoewel het partiële respons 
percentage hoger was in de axitinib-groep, 36% versus 18%, vertaalde dit zich niet 
naar een langere progressievrije overleving. De mediane OS was 18,9 maanden 
(95% BI 11,2–NA) in de axitinib-groep en 18,5 maanden (95% BI 13,7–NA) in de 
‘alleen chemotherapie’-groep (p=0,78). Deze resultaten zijn vrij goed voor beide 
groepen, maar kunnen worden verklaard door een selectiebias. Patiënten in deze 
studie moesten een goede performance status hebben en werden geacht een 
tweede thoracoscopie te kunnen ondergaan.
In het translationele deel van de studie toonden we aan dat behandeling met 
axitinib de vaatnieuwvorming van tumoren efficiënt voorkwam en de vaatrijping 
verbeterde in vergelijking met tumorbiopten van patiënten die alleen met chemo-
therapie werden behandeld. Er was een significante toename van de MVD in de 
tumorbiopten na behandeling met pemetrexed en cisplatin in vergelijking met 
biopsieën vóór behandeling (p<0,0001). Bovendien nam in deze groep het aantal 
onrijpe bloedvaten toe na chemotherapie (p=0,0003). Daarentegen bleven in de 
axitinib-groep de MVD en het aantal rijpe bloedvaten na behandeling hetzelfde. 
Analyse van mRNA-expressie toonde aan dat de meeste angiogene liganden en 
hun receptoren (FGF2, PDGFβ en in mindere mate PGF en hun overeenkomstige 
receptoren) na behandeling met axitinib waren toegenomen. Dit kan een rebound- 
effect zijn dat werd veroorzaakt door het stoppen van de behandeling met axitinib 
5 dagen voor de tweede thoracoscopie vanwege veiligheidsredenen. Het is ook 
mogelijk dat verhoogde mRNA-expressie van angiogene groeifactoren en hun 
receptoren een compenserende reactie was op de remming van het VEGF-signaal 
door axitinib. Het belang van niet alleen het controleren van de meest belangrijke 
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geachte VEGF/VEGFR2-signalering, maar ook het controleren van andere signale-
ringsroutes werd onderstreept door de bevinding dat verhoogde mRNA-expressie 
van vasculaire (PDGFRβ en FLT1/VEGFR1) en lymfatische (FLT4/VEGFR3) groei-
factor receptoren sterk gecorreleerd was met slechtere prognose; respons van de 
tumor werd alleen waargenomen bij patiënten met de laagste expressieniveaus.
Het toevoegen van translationeel onderzoek aan klinische onderzoek stelde ons 
in staat biomarkers te onderzoeken die het werkingsmechanisme van een nieuw 
medicijn ondersteunen (of afwijzen). Het feit dat we konden aantonen dat alleen 
het verminderen van MVD en het verhogen van de rijpheid van bloedvaten niet 
voldoende was om betere klinische resultaten bij patiënten te verkrijgen, onder-
steunt deze stelling.
Als laatste hebben we ons gericht op de mogelijke implementatie van een geop-
timaliseerd RECIST-model. De werkzaamheid van een behandeling bij patiënten 
wordt vaak gebaseerd op de afname van de tumor (respons) die wordt gezien op 
de CT scan. De indeling of classificatiecriteria voor de respons zijn optimaal als de 
radiologische beoordeling correleert met de overleving van de individuele patiënt.
De beoordeling van de radiologische respons bij patiënten met MPM is echter 
moeilijk. De verdikking van het borstvlies is vaak subtiel en daardoor niet altijd 
reproduceerbaar en het oppervlak van de tumor is vaak groot, omdat het de 
hele borstholte omvat. Bovendien zijn de afmetingen van de tumor meestal niet 
bolvormig, waardoor de afkapwaarden voor partiële respons (PR) en progres-
sieve ziekte (PD), oorspronkelijk ontworpen voor bolvormige tumoren, minder 
betrouwbaar zijn. In het verleden was het scoresysteem voor patiënten met MPM 
al verbeterd en gewijzigd naar ‘gemodificeerde RECIST’ (modified RECIST), maar er 
is nog steeds ruimte voor verbetering.
Onze analyse was gebaseerd op de C-statistiek. Dit is een methode die kijkt naar 
de discriminerende waarde van een test, namelijk het vermogen van de test om 
onderscheid te kunnen maken tussen mensen met een hoog en een laag risico, 
vergeleken met puur toeval. In het kort, wanneer de C-statistiek hoger is dan 0,7, 
worden de modellen over het algemeen als acceptabel beschouwd en met een 
C-statistiek >0,8 zeer acceptabel. In eerder werk van anderen (Labby) werd de 
afkapwaarde die de hoogste waarde van C opleverde bepaald in een mesotheli-
oomcohort. In dit cohort bleek -64% voor PR en +50% voor PD als beste respons 
of bij de eerste follow-upscan het meest effectief. Hiermee werd een C-statis-
tiek van 0,855 behaald. Om deze afkapwaarde waarden te evalueren, hebben we 




een subgroep van patiënten uit de NVALT 5-studie. We konden deze resultaten 
in ons patiënten cohort niet bevestigen. Terwijl de standaard gemodificeerde 
RECIST-criteria (PR -30% en PD +20%) in dit NVALT 5 cohort een C-statistiek van 
0,776 met een standaardfout van 0,057 opleverden, leverden de geoptimaliseerde 
RECIST-criteria (PR -64% en PD +50%) een C-statistiek van 0,737, lager dus dan de 
aanvankelijk gerapporteerde C-statistiek van 0,855.
De verschillen in uitkomst van de twee mesothelioom cohorten kunnen te wijten 
zijn aan de verschillende focus van deze onderzoeken. In de Labby-studie werden 
patiënten geëvalueerd die met chemotherapie werden behandeld, waarbij de 
groep met partiële respons beter vertegenwoordigd was. De NVALT-studie was 
een gerandomiseerde onderhoudsstudie na eerstelijnschemotherapie en van 
patiënten werd niet verwacht dat ze een respons hadden op de studiemedicatie/
palliatieve zorg, er waren dan ook maar een paar responders. Ons cohort had 
vanwege de selectiecriteria ook een hoger aantal patiënten die lang overleefden. 
We zullen moeten uitkijken naar een groter, uitgebalanceerd cohort om betere 
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Allereerst wil ik de patiënten bedanken die participeerden in ‘mijn’ studies. Voor de 
Thalidomidestudie werden ze in heel Nederland door mijn collega’s gevraagd om 
mee te doen, waarvoor ik ook hen wil bedanken. De Axitinibstudie draaide alleen 
in het Antoni van Leeuwenhoek, waardoor ik een groot deel van de patiënten 
persoonlijk kende. Het is spijtig dat ik ze niet meer van dit proefschrift op de 
hoogte heb kunnen stellen.
Mijn promotor Paul Baas, dierbare collega: dank voor de ruimte die je mij hebt 
geboden om mijzelf te ontwikkelen in het Antoni van Leeuwenhoek. Naast onze 
wekelijkse, of maandelijkse, besprekingen, heb je mij op de juiste momenten altijd 
goede adviezen gegeven en had je er plezier in om her en der wat zetjes te geven, 
of contacten aan te spreken, zodat het onderzoek weer in goede banen werd 
geleid. Ook de sociale aspecten zijn bij jou altijd van groot belang: naast de vele 
gezellige etentjes en uitstapjes, behoren onze reizen naar Kyoto en Tokio wat mij 
betreft zeker tot de hoogtepunten.
Mijn co-promotor Sjaak Burgers: zolang ik in het AVL werk zijn wij grotendeels 
kamergenoten geweest. Je bent mede hierdoor een van mijn beste collega’s 
geworden. Het is altijd fijn om op vrijdag weer even het leven binnen en buiten 
het ziekenhuis met je door te nemen. Ten aanzien van het onderzoek wil ik je 
danken voor je scherpe blik om niet lopende teksten weer leesbaar te maken en 
je vermogen om hoofd- en bijzaken te scheiden. Ook jij bent een fijne reisgenoot, 
we hebben met anderen veel meegemaakt en hadden een toptijd in Zuid-Afrika.
Het translationele deel van het onderzoek zou niet gelukt zijn zonder Marion 
Scharpfenecker, Tiny Korse en Arjan Griffioen. Gedurende de jaren dat we bezig 
waren met de Axitinibstudie heb ik genoten van onze bijeenkomsten om de resul-
taten en de volgende stappen te bespreken. Marion en Tiny, heel veel dank dat 
jullie mij bij de laatste loodjes helpen om dit promotieproces door te komen!
Suzanne Onderwater, we zaten met Paul wekelijks bij elkaar om de follow-up van 
de Axitinibpatiënten te bespreken, waarvan jij er ook veel hebt begeleid. Jij hebt 
de taak op je genomen om de klinische data te verzamelen en dat kon ik gerust aan 
je overlaten! Als we elkaar nu in het AVL tegenkomen is het altijd nog heel gezellig.
Collega’s die door de jaren heen voor mij klaar hebben gestaan, ook voor alle dingen 
die mij weer eens niet lukten: mooie lay-out van posters maken, tabellen aanpassen, 
PDF’s omzetten, gegevens verzamelen en noem maar op: Mariëlle, Daphne, 
Annemieke, Ilse, Marianne, Bernadette, Bea, Marion, Angela, heel erg bedankt!
Dankwoord
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Collega’s van de Thoraxoncologiegroep: Egbert, Joop, Willemijn, Gerrina, Laurie, 
Wendy, Bianca, Jasper, Frank, Merel, Tijmen, Emmy, Marloes, Bodien, Sally-Ann, 
Ben, Juanita, Marguerite, Inge, Marieke, Marit, alle arts-assistenten, José, Judi, 
Joost, Renske, Margriet, Monique, Houke, Koen, Xander, Ferry, Thierry, Annema-
rieke, Rianne, Kim, Liudmila, Elise, Emilia, Marcel en Zing, door jullie voel ik me 
op mijn gemak in het AVL en het is fijn om met jullie samen te werken. En voor 
sommigen: hoe heerlijk is het om niet meer de beruchte vraag te hoeven beant-
woorden: “heb je al een datum”?
Dianne de Gooijer, jij bent een fijne, goedlachse, hardwerkende collega. Ontzet-
tend leuk dat jij de gegevens van de Thalidomide- en Axitinibpatiënten hebt 
gebruikt voor verder onderzoek. Dank voor al je hulp en niet te vergeten: zonder 
jou was het me nooit gelukt om een datum te krijgen in het LUMC.
Pieter, sinds onze studententijd eten wij regelmatig samen met Karin en Marieka 
op zondagavond en delen lief en leed. Ik ben heel erg blij dat ik jou als paranimf 
aan mijn zijde heb.
Anne-Marie, eerst mijn BFF, daarna getuige op ons huwelijk en nu paranimf op 
mijn promotie. Ik hoef je verder niet uit te leggen wat onze vriendschap voor mij 
betekent.
Familie en schoonfamilie, eindelijk is het af! Dank voor jullie jarenlange belangstel-
ling en steun.
Lieve Derk en Boris, familie en vrienden voor het leven. Jullie maken ons leven 
licht, telkens weer opnieuw.
Lieve papa, het is al lang geleden, maar mijn onbezorgde jeugd en de steun die je 
mij gaf tijdens mijn studie, hebben mij gemaakt tot wie ik ben. Jij leerde mij dat 
zelfstandigheid in het leven belangrijk is, dank daarvoor.
Lieve Ebbie, Bent, Tjerk en Broer, wat ben ik blij dat jullie in mijn leven zijn. Daardoor 










Wieneke Buikhuisen werd op 4 november 1965 geboren in het Academisch Zieken-
huis te Leiden.
Zij doorliep met veel plezier het Haags Montessori Lyceum in Den Haag en maakte 
daar kennis met het adagium ‘leer het mij zelf doen’. 
Haar studie geneeskunde startte in 1986 aan de Universiteit van Amsterdam. In 
1989 vertrok zij voor de wetenschappelijke stage een half jaar naar Boston, waar 
zij onder leiding van Dr. John F. Thompson aan de Tufts University onderzoek deed 
naar de basale functies van de EGF-receptor. Het doen van onderzoek en het vrije 
leven in de Verenigde Staten beviel haar zo goed, dat zij, nadat het vierde jaar 
van de studie was afgerond, voor een jaar naar Philadelphia ging. Ze deed daar 
basaal wetenschappelijk onderzoek naar leverregeneratie onder leiding van Dr. 
Barbara A. Haber aan het Howard Hughes Institute, verbonden aan de University 
of Pennsylvania. In 1992 won zij met dit onderzoek de American Gastroenterolo-
gical Association Student Abstract Prize. 
Tussen 1992 en 1994 doorliep zij haar coschappen in diverse ziekenhuizen in 
Amsterdam en omstreken. Na een periode als AGNIO inwendige geneeskunde te 
hebben gewerkt in het Academisch Medisch Centrum te Amsterdam, begon zij in 
1996 de opleiding tot internist onder leiding van Prof. Dr. L. Arisz en Dr. J. Silberbush 
in respectievelijk het AMC en het Onze Lieve Vrouwe Gasthuis te Amsterdam. In 
2001 behaalde zij haar diploma. Tijdens haar opleiding maakte zij echter kennis met 
de longziekten en zij realiseerde zich dat een combinatie van systemisch denken en 
werken met de handen, in een vakgebied waar ze de patiënt grotendeels zelf kon 
analyseren en behandelen, haar het meeste aansprak. 
Van 2001 tot 2004 deed zij daarom de vervolgopleiding Longziekten en Tubercu-
lose in het Onze Lieve Vrouwe Gasthuis onder leiding van Dr. A.J.M. Schreurs en Dr. 
H.B. Kwa. In 2003 volgde zij een academische stage bij Prof. Dr. P.E. Postmus aan 
de Vrije Unversiteit, voor een verdieping in de longoncologie. Zij denkt nog steeds 
met genoegen terug aan haar opleidingsperiode, waarbij er in zowel het AMC, het 
OLVG als het VUMC naast hard werken ook veel ruimte was voor gezelligheid en 
zelfontplooiing. 
Vanaf 2005 is zij werkzaam in het Antoni van Leeuwenhoek in Amsterdam. Zij 
bekwaamde zich in die tijd in de endo-echografische technieken EUS en EBUS. Zij 
specialiseerde zich in neuro-endocriene tumoren van de long, waarvoor het Long-
NET-team in 2020 als een van de eersten het certificaat Center of Excellence van 
Curriculum vitae
166
de European Neuroendocrine Tumour Society behaalde. Daarnaast heeft zij zich 
al die jaren met veel plezier met de behandeling en het onderzoek van mesothe-
lioompatiënten bezig gehouden. Dit heeft uiteindelijk geleid tot dit promotieon-
derzoek, dat onder leiding van Prof. Dr. P. Baas werd uitgevoerd.
Wieneke is gelukkig getrouwd met Egbert van Schoten en samen hebben zij 3 
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